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ABSTRACT
Members of the STAT transcription factor family are expressed in adipocytes, including
STATs 1, 3, 5A, 5B, and 6. Although STATs 1 and 5 proteins are known to be induced during
adipogenesis, the functions of these STATs in mature adipocytes are not known. Hence we have
sought to identify adipocyte genes which are transcriptionally regulated by STATs to elucidate a
role of these proteins in fat cells. We have characterized STAT binding sites in the promoters of
four adipocyte genes, PPARγ2, LPL, FAS and C/EBPδ. PPARγ2 expression decreases in
adipocytes following exposure to IFNγ, an activator of STAT1. IFNγ induces the binding of
STAT1 to a site in the PPARγ2 promoter. Furthermore, the STAT1 binding site is required for
IFNγ regulation of the PPARγ2 promoter in vitro. Although both CT-1 and LIF induced STAT1
binding to the PPARγ2 promoter, only CT-1 substantially modulated expression of PPARγ2. We
have also identified a STAT1 binding site in the promoter of LPL, which is bound by STAT1
following treatment of 3T3-L1 adipocytes with IFNγ. In addition, LPL protein levels are
downregulated by IFNγ treatment. Treatment with PRL, an activator of STAT5A, decreased
levels of FAS protein and mRNA in adipocytes. Regulation of the rat FAS promoter by PRL
required a region of the promoter which contained a STAT5 binding site. Binding to this site by
STAT5A was activated by PRL treatment and was highly specific. Finally, in our analysis on
the effects of LIF on adipocytes, we determined that the expression SOCS3 and C/EBPδ mRNA
transiently increases following treatment of adipocytes with LIF. We identified three STAT1
binding sites within the C/EBPδ promoter, which we hypothesize mediate the induction of
C/EBPδ by LIF. Although LIF did not profoundly affect adipogenesis or basal and insulinstimulated glucose uptake, chronic treatment with LIF abrogated the level of SREBP1 and FAS
proteins. In summary, our studies suggest that STAT1 and STAT5 serve to limit synthesis of

ix

lipids in mature fat cells, limiting expansion of adipocytes and accretion of adipose tissue. The
identification of PPARγ, FAS, and LPL as STAT-regulated genes provides insight into the
molecular mechanisms of energy homeostasis, adipocyte physiology and the action of cytokines
in fat.

x

CHAPTER 1: INTRODUCTION
1.1 Obesity and Adipocytes
During the past two decades obesity has become an epidemic. The prevalence of obesity
is rapidly on the rise not only in industrialized nations, but also in countries with developing
economies (Speakman, 2004). In the United States of America, more than 50% of the population
is overweight and nearly 20% are obese (Speakman, 2004). Recent heightened awareness and
interest in obesity has lead to the development of public health strategies that promote healthy
eating and physical fitness and has made evident the importance of research in the field of
obesity.
Industrialization is correlated with population trends of increased food intake and
decreased physical activity, the so-called Western lifestyle (reviewed in French et al., 2001). In
the last 30 years, overall availability of energy from food per person in the United States has
increased 15%. Furthermore, in the same period of time, consumption of milk has declined by
over 20%, while soft drink consumption has more than doubled, concurrent with the increased
intake of sugar. Moreover, the frequency of eating away from home, particularly at fast food
restaurants has increased, where increased portion sizes and high density of calories and fat
result in underestimation of actual food consumption. Energy expenditure in the American
population has declined as television viewing has replaced more physically engaging leisure
activities and as car ownership has become widespread. In addition, labor-saving technological
advances have decreased the physical activity of household chores and workplace tasks. In the
last century, service and high technology careers have become the more prevalent types of work,
a shift from the heavy manual labor of farming, carpentry, and factory work. Clearly, there are
multiple environmental causes of the obesity epidemic in societies of affluence.
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Obesity is most commonly defined by body mass index (BMI), calculated as weight in
kilograms divided by height in meters squared (Speakman, 2004). A BMI between 18.5 and
24.9 is considered normal, the BMI of overweight individuals is between 25 and 29.9, and over
30.0 is considered obese (Speakman, 2004). BMI is a reliable measure of body composition only
if body fatness varies with body weight but is not a good indicator for athletes with increased
muscle mass or the elderly who may have disproportionately less lean mass (Speakman, 2004;
Elia, 2001). Other measures of body fat include ratio of waist and hip circumferences,
underwater weighing, skin fold measurement, and electrical impedance (Bray, 2001).
As the prevalence of obesity increases, the health care costs of obesity are rising as well
and are estimated to be 7% of the total health costs in the United States (Colditz, 1999). The
costs associated with obesity are mainly not due to obesity itself, but instead, are attributable to
several obesity-related diseases: diabetes, heart disease, hypertension, stroke, gall bladder
disease, renal disease, cancer, liver disease, and osteoarthritis (Speakman, 2004). The risks of
these diseases decrease with even moderate weight loss (Visscher and Seidell, 2001). Obesity is
associated with a tenfold increase in risk of type 2 diabetes, the most expensive consequence of
obesity (Carey et al., 1997).
Diabetes is a disease characterized by increased levels of blood glucose. Type 1 diabetes
or juvenile diabetes, is an autoimmune disease in which the insulin-producing pancreatic beta
cells are destroyed (Dean and McEntyre, 2004). Over 16 million Americans have type 2
diabetes or noninsulin dependent diabetes mellitus (NIDDM), which is generally associated with
insulin resistance, resulting in decreased uptake of glucose by muscle and adipose tissue and a
failure to suppress glucose production in the liver (Dean and McEntyre, 2004). Increased levels
of free fatty acids in circulation are associated with excess adiposity (Boden, 1997). Free fatty
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acids impair insulin action at multiple levels, decreasing glucose uptake and oxidation in insulinsensitive tissues (Boden, 1997), attenuating the inhibitory effect of insulin on hepatic glucose
output (Boden, 1997), and inducing apoptosis in pancreatic β cells, resulting in decreased insulin
secretion (Cnop et al., 2001). Lipotoxicity may not be the only molecular link between obesity
and diabetes, as multiple adipocyte-derived messengers have been identified that affect insulin
sensitivity.
Obesity results from both quantitative and qualitative changes in adipose tissue.
Adipocytes have the unique capacity to store substantial volumes of lipid in the form of
triglycerides as energy intake exceeds energy needs and to mobilize lipids as free fatty acids to
supply the energy needs of other tissues (Rosen and Spiegelman, 2000). Adipocytes expand to
the maximum volume, and then the tissue increases the number of cells to accommodate the
storage needs (Rosen and Spiegelman, 2000). While the major function of white adipose tissue
(WAT) is storage, brown adipose tissue (BAT) dissipates energy as heat through the uncoupling
of respiration from the synthesis of ATP which is conferred by increased number of
mitochondria and expression of uncoupling protein-1 (Nedergaard et al., 1986). BAT may also
function to protect against obesity. Depots of brown adipocytes are highly diminished in adult
humans, but are more prominent in mature rodents (Nedergaard et al., 1986).
The concept of the adipocyte as a dynamic component of energy homeostasis was
proposed many years ago (Kennedy, 1953), but only recently has there been evidence to support
this hypothesis through the identification of secreted molecules from adipocytes. These include
hormones: leptin and resistin; cytokines: tumor necrosis factor α (TNFα) and interleukin 6 (ILs); peptides: plasminogen activator inhibitor-1 and angiotensinogen; and adipokines: adiponectin
and adipsin; in addition to free fatty acids and glycerol (Frühbeck et al., 2001). These products
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of adipocytes have autocrine, paracrine, and endocrine effects, forming signaling circuits with
the hypothalamus, pancreas, liver, skeletal muscle, kidneys, endothelium, and immune system to
regulate energy homeostasis, insulin sensitivity, satiety, and vascular function (Frühbeck et al.,
2001). These factors also exhibit altered levels in the condition of obesity, fasting, and
refeeding, indicative of their importance in metabolism (Rosen and Spiegelman, 2000). In
addition, adipocytes are responsive to many signals originating from other tissues (Frühbeck et
al., 2001).
Although a previous hypothesis suggested that people are born with all of the adipocytes
they would need, there is substantial evidence that adipogenesis occurs throughout the life of an
organism (Prins and O’Rahilly, 1997). New adipocytes arise due to normal cell turnover and to
meet requirements for increased energy storage (Prins and O’Rahilly, 1997). In vivo, the
development of white adipose tissue (WAT) begins just prior to birth, with a rapid expansion
following birth (Gregoire et al., 1998). The early events of adipogenesis, committing
mesodermal precursor cells to preadipocytes are not well understood; however, the proliferation
of a network of capillaries in a region of subcutaneous loose connective tissue is considered
primitive adipose tissue (Rosen and Spiegelman, 2000). Several molecular events and
transcriptional pathways that govern differentiation of preadipocytes to adipocytes have been
identified. These discoveries were possible largely due to the establishment of the 3T3-L1 and
3T3-F442A preadipocyte cell lines from the Swiss 3T3 cells derived from 17- to 19-day mouse
embryos (Green and Meuth, 1974; Green and Kehinde, 1975; 1976). Preadipocytes are
morphologically indistinguishable from fibroblasts; yet they are committed to the adipocyte
lineage (Rosen and Spiegelman, 2000). The first stage of differentiation is growth arrest, which
is achieved in culture by contact inhibition and by the addition of a differentiation promoting
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cocktail of hormones, methylisobutylxanthine (MIX), dexamethasone, and insulin (Green and
Kehinde, 1975). The effects of insulin on preadipocytes are not mediated by the insulin receptor,
but instead occur through activation of the insulin-like growth factor 1 receptor (IGF-1 R). This
cross-activation by insulin occurs with a super physiological dose of insulin (Rosen and
Spiegelman, 2000). Stimulation of the IGF-1 R activates the Ras/mitogen activated protein
kinase (MAPK) pathway and Akt (Rosen and Spiegelman, 2000). Constitutively active Akt has
been shown to induce spontaneous adipogenesis in 3T3-L1 cells, indicating that Akt may be the
critical signaling cascade activated by the IGF-1 R (Magun et al., 1996). MIX is a
phosphodiesterase inhibitor which increases levels of cAMP (Rosen and Spiegelman, 2000).
Although MIX has other effects, the predominant effector of differentiation is likely cAMP
(Yarwood et al., 1995). Dexamethasone is a synthetic glucocorticoid activating the
glucocorticoid receptor (GR). There is evidence to indicate that dexamethasone inhibits the
expression of preadipocyte factor-1 (Pref-1), a protein that has anti-adipogenic properties (Smas
et al., 1999). These three agents accelerate adipogenesis under serum-free conditions, but their
effects on adipogenesis are potently effective in the presence of fetal calf serum. One component
of fetal calf serum that appears to mediate the proadipogenic effects is growth hormone (GH),
which has been shown to induce differentiation in multiple cell lines (Catalioto et al., 1992;
Tominaga et al., 2002; Stewart et al., 2004). Yet, GH inhibits differentiation of primary
preadipocyte cultures (Hausman and Martin, 1989; Wabitsch et al., 1996; Hansen et al., 1998),
indicating that the effects of GH depend on the stage of differentiation.
Following growth arrest, preadipocytes undergo clonal expansion followed by a second
phase of growth arrest which is associated with changes in expression of several proteins
involved in cell cycle control, p18, p21, and p27 (Morrison and Farmer, 1999) and the initiation
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of a transcriptional cascade. CCAAT/enhancer binding protein-δ (C/EBPδ) and C/EBPβ are
transiently induced by dexamethasone and MIX, respectively (Cao et al., 1991; Wu et al., 1996),
which is followed by the expression of two transcription factors that are highly adipogenic,
peroxisome proliferator-activated receptor-γ (PPARγ) and C/EBPα. PPARγ induces growth
arrest through upregulation of p18 and p21 (Rosen and Spiegelman, 2000) and has been shown
to activate the expression of several adipocyte marker proteins, such as fatty acid binding protein
aP2 and phosphoenolpyruvate carboxykinase (Tontonoz et al., 1994; 1995). Following the
second phase of growth arrest, cells acquire a round morphology, accumulate lipid, become
insulin sensitive (MacDougald and Lane, 1995) and express genes that are associated with the
adipocyte phenotype, aP2, glycerophosphate dehydrogenase, lipoprotein lipase (LPL), fatty acid
synthase (FAS), signal transducer and activator of transcription 5 (STAT5), glucose transporter 4
(GLUT4), and the insulin receptor (IR) (Spiegelman et al., 1993; Stephens et al., 1996).
The cell lines, 3T3-L1 and 3T3-F442A, in addition to other adipocyte cell models, exhibit
many features of in vivo adipocytes, but they do not perfectly recapitulate adipose tissue. Cell
lines synthesize and secrete relatively low levels of leptin and TNFα in comparison to in vivo
adipose tissue (Rosen and Spiegelman, 2000). Furthermore, cell lines do not exhibit the depotspecific characteristics that have been demonstrated for perigonadal, omental, retroperitoneal and
subcutaneous fat depots (Ostman et al., 1979; Djian et al., 1985; Adams et al., 1997; Morimoto
et al., 1997; Lefebvre et al., 1998). Moreover, the use of cell lines does not include the inputs
from the matrix of connective tissue, neurons or stromovascular cells that are part of the adipose
tissue (Rosen and Spiegelman, 2000). In spite of these caveats, studies of adipocyte function
using cell lines are extremely useful and have yielded valuable insights into adipocyte biology.
Cell lines are a uniform population of cells which simultaneously differentiate in culture, unlike
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the diffuse adipocyte precursors in adipose tissue and heterogeneous primary cultures which
cannot be synchronized (Ntambi and Young-Cheul, 2000). Moreover, primary cultures require a
large amount of fat tissue and have a limited lifespan in culture, unlike cell lines which may be
passaged many times (Ntambi and Young-Cheul, 2000). Therefore, the 3T3-L1 cells, in addition
to other adipocyte cell lines, are ideal for many investigations of adipocyte differentiation.
Since obesity is an excessive accumulation of adipocytes, the study of adipogenesis and
adipocyte biology is important for understanding not only the causes of the disease, but also to
develop therapies for obesity. Importantly, a better understanding of adipocyte physiology is
necessary for treatment of the diseases associated with obesity.
1.2 Adipocyte Proteins
PPARγ
PPARγ is a member of the nuclear hormone receptor family, a group of transcription
factors which are activated by small, lipophilic ligands (Egea et al., 2000). PPARγ was
discovered as a transcription factor that bound to the enhancer of aP2 (Tontonoz et al., 1994a)
and is known to exist as four isoforms, PPARγ1, 2, 3, and 4, produced by differential promoter
usage and alternative splicing (Zhu et al., 1995; Fajas et al., 1998; Sundvold et al., 2001).
PPARγ1, 2 and 3 are all expressed in adipose tissue, but PPARγ1 is present at low levels in
multiple tissues, PPARγ3 is also expressed in large intestine, and PPARγ4 tissue distribution is
not known (Tontonoz et al., 1994a; Chawla et al., 1994; Fajas et al., 1998; Sundvold and Lien,
2001).
PPARγ has been implicated in the regulation of systemic insulin sensitivity, particularly
through the insulin-sensitizing effects of the synthetic PPARγ ligands, thiazolidinediones (TZDs)
(Lehmann et al., 1995). TZDs decrease the production of TNFα and resistin, two secreted
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products of adipocytes which promote insulin resistance (Peraldi et al., 1997; Steppan et al.,
2001), promote synthesis of adiponectin, an insulin sensitizer (Yamauchi et al., 2001), and
improve the ability of adipose tissue to store lipid (Evans et al., 2004). Direct evidence for the
association between PPARγ and insulin sensitivity comes from genetic studies showing that
mutations in the ligand-binding domain of PPARγ are associated with severe insulin resistance in
humans (Barroso et al., 1999).
PPARγ is also considered a master regulator of adipocyte differentiation as PPARγ is
highly induced during adipogenesis and the ectopic expression of PPARγ effectively converts
nonprecursor fibroblast cells into adipocytes (Tontonoz et al., 1994b). Although transgenic mice
that only express one copy of the PPARγ gene are more sensitive to insulin and are resistant to
diet induced obesity (Miles et al., 2000), the tissue-specific knockout of PPARγ in mature fat
tissue results in loss of adipose tissue mass, hyperlipidemia, and hepatic insulin resistance (He et
al., 2003). These findings reveal the importance of precise regulation of PPARγ expression for
whole body glucose metabolism and the development and maintenance of adipose tissue.
Regulation of PPARγ expression occurs at the levels of transcription and protein stability.
E boxes in the promoters of PPARγ1 and PPARγ3 have been characterized as sites for regulation
by SREBP1 (Fajas et al., 1999). Liver X receptor (LXR) upregulated PPARγ expression during
adipogenesis through an LXR site in the PPARγ2 promoter (Seo et al., 2004). Krüppel-like
factor 2 inhibits PPARγ2 expression in preadipocytes through two tandem Krüppel binding sites
in the promoter (Banerjee et al., 2002). A STAT5B binding site in the human PPARγ3 promoter
was identified as a polymorphism governing height and lipid metabolism (Meirhaeghe et al.,
2003). Moreover, binding sites for C/EBP proteins have been characterized (Elberg et al., 2000;
Tang et al., 2003). Degradation of PPARγ protein occurs under basal conditions and following
8

stimulation by TZDs (Hauser et al., 2000) and IFNγ (Waite et al., 2001). IFNγ treatment of 3T3L1 adipocytes also decreased PPARγ expression by regulating synthesis of PPARγ mRNA
(Waite et al., 2001). PPARγ expression was transiently decreased following treatment of 3T3L1 adipocytes with the gp130 cytokine, cardiotrophin-1 (CT-1) independent of the MAPK
pathway (Zvonic et al., 2004). Thus, signaling pathways activated by these cytokines likely
contribute to the regulation of PPARγ expression in adipocytes.
C/EBPδ
C/EBPδ is a basic-leucine zipper transcription factor and is one of six members of the
C/EBP family of transcription factors (Tanaka et al., 1997). Members of the C/EBP family
contain the basic leucine zipper dimerization domain, as well as basic and acidic DNA binding
domains (Belmonte et al., 2001). C/EBP proteins form homo- and heterodimers, and all bind the
same cis-regulatory elements in promoters (Tanaka et al., 1997). C/EBPδ is expressed at a low
level in most tissues (Huang et al., 2004), but is rapidly induced by several cytokines and
neurotransmitters (Takiguchi, 1998; Ramji and Foka, 2002). C/EBPδ, along with C/EBPβ, is
part of a transcriptional cascade that directs adipogenesis (Lane et al., 1999). Double knockout
of C/EBPβ/δ inhibits fat tissue development in vivo and adipogenesis in cultured mouse
embryonic fibroblasts (MEFs) (Tanaka et al., 1997). Adipogenesis is recovered with the ectopic
expression of PPARγ in these double knockout MEFs, yet these adipocytes exhibit decreased
expression of IRS-2 and GLUT4 (Yamamoto et al., 2002). Thus, C/EBPs are regulators of
glucose uptake and insulin sensitivity and have nonoverlapping roles in adipocytes.
Lipoprotein Lipase (LPL)
LPL is a member of the lipase family which also includes hepatic lipase and pancreatic
lipase. These enzymes likely evolved from a common ancestral gene that encoded a digestive
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lipase in the intestine (Kirchgessner et al., 1989). LPL catalyzes the hydrolysis of serum
triglycerides from very low density lipoproteins and chylomicrons for uptake of free fatty acids
(Braun and Severson, 1992). LPL is present in many tissues, but the majority of the enzyme
originates as a secreted protein from skeletal muscle and adipose tissue (Knutson, 2000). The
functionally active form of LPL is a glycoprotein anchored by heparan sulfate proteoglycan to
the surface of capillary endothelial cells and provides free fatty acids to the underlying tissues
(Braun and Severson, 1992). In WAT, free fatty acids are re-esterified for storage as
triglycerides, whereas in BAT the activity of LPL regulates thermogenesis (Braun and Severson,
1992). In other tissues, such as skeletal muscle and cardiac muscle, the released free fatty acids
are used as a primary energy source (Braun and Severson, 1992).
LPL deficiency in humans is a rare autosomal recessive disorder resulting in fasting
hypertriglyceridemia, accumulation of chylomicrons, elevated serum cholesterol and failure to
thrive, but it does not cause any apparent defects in the development of adipose tissue (Brun et
al., 1989). The transgenic knockout of LPL in mouse results in a very similar phenotype, but the
mice die within 30 hours of birth (Coleman et al., 1995; Weinstock et al., 1995). Moderate
overexpression of LPL in skeletal muscle of obese rodents protects against diet-induced obesity
(Jensen et al., 1997). Yet, the white adipose tissue-specific knockout of LPL also protected
obese rodents against diet-induced obesity (Weinstock et al., 1997). However, high levels of
LPL expression have been correlated with obesity in humans and rodents (Maggio and
Greenwood, 1982; Greenwood, 1985). Thus, the tissue-specific expression of LPL has profound
effects on energy partitioning.
Regulation of LPL is complex and occurs at the levels of transcription, translation, and
post-translational processing, indicative of the importance of LPL in meeting the varying
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metabolic demands in tissues (Braun and Severson, 1992). LPL is sensitive to regulation by
steroids, temperature, feeding, and catecholamines in a tissue-specific manner (Greenwood,
1985; Braun and Severson, 1992). Fasting decreases activity of LPL in WAT, but increases LPL
activity in heart (Braun and Severson, 1992). Refeeding and insulin have been shown to increase
LPL activity in WAT (Braun and Severson, 1992). Furthermore, cold exposure activates LPL in
BAT (Braun and Severson, 1992). Taken together, these findings indicate that the tissue-specific
regulation of LPL expression is critical for lipid metabolism and homeostasis. In addition, LPL
activity and expression are regulated by cytokines, TNFα, IFNα, and IFNγ, in 3T3-F442A
adipocytes (Doerrler et al., 1994). In spite of these findings, little is known about the
mechanisms of transcriptional regulation of LPL, and it is an important area of research.
Fatty Acid Synthase (FAS)
When energy intake exceeds energy expenditure, white adipose tissue stores excess
calories as triglycerides. Although the majority of stored lipids come from diet, the production
of long chain fatty acids from carbohydrate sources by de novo lipogenesis is an important
contribution to total body lipid stores, particularly under the condition of a high carbohydrate
diet (Sul and Wang, 1998). FAS is the central enzyme of de novo lipogenesis, synthesizing
palmitate from malonyl CoA generated from glycolysis (Sul and Wang, 1998). Transgenic
knockout of FAS in mice results in preimplantation embryonic death (Chirala et al., 2003).
Heterozygotes die throughout embryonic development, yet some survive through maturity
(Chirala et al., 2003). Thus de novo lipogenesis is important in embryonic development. C75,
α-methylene-γ-butyrolactone, is a pharmocological allosteric inhibitor of FAS (Kuhajda et al.,
2000). C75 administration results in weight loss in rodents, but this effect is more likely
mediated by decreased food intake due to increased production of an anorexin, neuropeptide Y,
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in the hypothalamus, than the direct inhibition of FAS in adipose tissue (Loftus et al., 2000). In
cultured 3T3-L1 cells, C75 decreases the activity of GPDH, accumulation of lipid and expression
of PPARγ, hallmarks of adipogenesis, strongly suggesting that FAS activity is an important
determinant of adipogenesis (Liu et al., 2004). These findings underscore the importance of
FAS activity and de novo lipogenesis in adipocyte function.
FAS is a large multifunctional monomer composed of seven catalytic domains: β
ketoacyl synthetase, acetyl-CoA transacylase, malonyl-CoA tranacylase, dehydratase, enoyl
reductase, ketoacyl reductase and thioesterase, in addition to an acyl carrier domain (Smith,
1994). The animal FAS gene is large, and the rat FAS gene is comprised of 43 exons and 42
introns (Sul and Wang, 1998). The FAS monomer likely resulted from gene fusion, as the
equivalent enzyme in bacteria and plants is a multi-enzyme complex (Smith, 1994). Fusion of
the separate genes likely evolved as spatial proximity of catalytic domains, stabilization of the
macromolecular structure, and perhaps most importantly, the coordinate regulation of the partial
catalytic activities were optimized (Smith, 1994).
The regulation of FAS occurs primarily at the level of transcription, as no known in vivo
allosteric inhibitors have been identified (Sul and Wang, 1998). FAS is exquisitely sensitive to
nutritional and hormonal regulation (Sul and Wang, 1998). Expression increases following
feeding and in response to increased insulin levels (Moustaid et al., 1993; Soncini et al., 1995;
Kim et al., 1998; Rufo et al., 1999; Moon et al., 2000). Multiple insulin response elements have
been identified and include E boxes, bound by upstream stimulatory factor-1 (USF-1) (Wang and
Sul, 1995) and steroid response elements (SRE) bound by SREBP1 (Kim et al., 1998). Thyroid
hormone, which increases during refeeding, increases FAS activity and expression in cultured
3T3-L1 adipocytes and rat adipose tissue (Moustaid and Sul, 1991; Blennemann et al., 1995).
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Moreover, a thyroid hormone response element which activates transcription of FAS has been
characterized in the human FAS promoter (Xiong et al., 1998). The repression of FAS
expression in cultured rat white adipose tissue has also been demonstrated with fasting and in
response to glucagon, a hormone which raises intracellular levels of cAMP (Foufelle et al.,
1994). Although an inverted CCAAT box, a cAMP response element, has been identified, it is
not clear how cAMP regulates FAS expression, as the inverted CCAAT box is bound by basal
transcription factors which are not regulated by cAMP or glucagon (Rangan et al., 1996; Roder
et al., 1997). In two independent studies, dexamethasone was shown to increase the expression
of FAS in cultured rat adipocytes (Reul et al., 1997) and the activity of the FAS promoter in
adipose tissue (Freak and Moon, 2003). Yet, inhibition of FAS expression by dexamethasone
has also been observed (Foufelle et al., 1994). The discrepancy in these effects may depend on
the nutritional state of the organism. GH, an important developmental cytokine, abrogates the
induction of FAS expression by insulin and down regulates basal expression of FAS in 3T3F442A cells (Yin et al., 2001a; 2001b), yet a GH responsive region of the FAS promoter has not
been identified. The identification of these and other regulatory elements in the FAS promoter
are indicative of the complex and precise regulation of FAS and de novo lipogenesis in adipose
tissue.
1.3 JAK/STAT Signaling
Some extracellular signaling molecules transmit signals through transmembrane receptors
to the Janus kinase (JAK)/signal transducers and activators of transcription pathway (STAT) to
regulate gene expression. The JAK/STAT pathway integrates multiple intercellular signals to
initiate cell and tissue responses to stress, modulate development and regulate homeostasis.
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The JAK/STAT pathway is the predominant signaling cascade for cytokines and is
initiated by the binding of a ligand to its cognate receptor (reviewed in Kisseleva et al., 2002).
Cytokine receptors lack intrinsic kinase activity, but undergo conformational changes in the
cytoplasmic domains, which activate the associated JAK. JAKs are non-receptor tyrosine
kinases which transphosphorylate the tyrosine residues on the cytoplasmic portion of the receptor
that serve as STAT-docking sites. STAT proteins are latent transcription factors, residing in the
cytoplasm and bind to the phosphorylated tyrosines through their src homology 2 (SH2) domain,
bringing the STATs within close proximity to the JAKs. The JAKs then phosphorylate the
STATs on a single, conserved tyrosine located just carboxy terminal to the SH2 domain. Upon
phosphorylation, STATs dissociate from the receptor and form either homodimers or
heterodimers with other phosphorylated STAT proteins. STAT dimers rapidly translocate to the
nucleus to bind specific DNA elements to modulate transcription.
JAKs are a family of kinases named after Janus, the two-faced Roman god of doors and
gates, for their two hallmark domains, the catalytic domain and a noncatalytic pseudokinase
domain (reviewed in Leonard and O’Shea, 1998). Four members have been identified, JAKs 1-3
and Tyk2, and are expressed ubiquitously, except for JAK3, which has limited expression in
natural killer cells, thymocytes, B cells, myeloid cells, vascular smooth muscle cells and
endothelium. The JAK homology (JH) 1 domain is the catalytic domain with all the features and
subdomains of other tyrosine kinase domains. JH2 is the psuedokinase domain which has very
similar features of a tyrosine kinase domain and may regulate regulate JAK catalytic activity.
The domains JH3-7 are relatively divergent among JAK proteins and have been implicated in
receptor association.
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Seven STATs have been identified, STATs 1, 2, 3, 4, 5A, 5B, and 6 which range in size
from 750 to 850 amino acids in length (Kisseleva et al., 2002). The STAT family likely resulted
from duplication of a primordial gene, as indicated by the presence of STAT homologues in
lower eukaryotes: Dictyostelium, C. elegans and Drosophilia (Miyoshi et al., 2001), and by the
clustering of stat genes on chromosomes (Choi et al., 1996; Lin et al., 1996; Leek et al., 1997;
Yamamoto et al., 1997).
STATs are comprised of 5 conserved domains and a variable C-terminal domain (Chen et
al., 1998). The amino terminus is comprised of 130 amino acids, which serve to promote the
cooperative binding to multiple consensus sites within a promoter (Vinkemeier et al., 1996;
1998). The coiled-coil domain of 4 α-helices forms a hydrophilic surface for interaction with
other proteins (Chen et al., 1998). The DNA binding domain (DBD) is a β-barrel and is similar
to the DBDs of NF-κB and p53 (Chen et al., 1998). This domain includes a nuclear export
signal (Mowen et al., 2000; McBride et al., 2000) in addition to a non-canonical nuclear
localization sequence (Melen et al., 2001). The linker domain contacts the DBD and the SH2
domain and may facilitate conformational changes of the STAT protein (Chen et al., 1998). The
SH2 domain is comprised of two anti-parallel β-strands contacting two α-helices and binds to a
phosphorylated tyrosine within a specific motif, mediating contacts with other proteins (Chen et
al., 1998). The conserved tyrosine is a few amino acids distal to the SH2 domain.
Phosphorylation of this tyrosine is necessary for activation, dimerization and nuclear
translocation (Ihle, 2001). The domain that is divergent for each STAT is the transcriptional
activation domain (TAD). This domain is thought to make contact with other transcriptional
regulators that modify the chromatin or contact the transcriptional machinery (Kisseleva et al.,
2002).
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STAT1 was the first discovered STAT, identified as the transcription factor that bound
IFNα/β recognition sequences upon activation by IFNα/β (Levy et al., 1988). STAT1 can
function as a homodimer, a heterodimer with STAT3 or as a trimer with STAT2 and
p48/interferon regulated factor 9 (IRF-9) (Kisseleva et al., 2002). The transgenic knockout of
STAT1 in mouse indicated that this protein has a crucial role in the innate immune response
(Meraz et al., 1996). STAT1-/- mice exhibited defective IFN-dependent immune response to
viral and microbial infection and were defective in chondrocyte proliferation (Meraz et al.,
1996).
STAT3 was initially identified as acute phase response factor (APRF; Akira et al., 1994)
which bound to IL-6 response elements/STAT induced elements (IRE/SIE; Lutticken et al.,
1994). STAT3 expression is nearly ubiquitous. Transgenic knockout of STAT3 in mice resulted
in lethality early in embryogenesis, around embryonic day 7.5 (Takeda et al., 1997) indicating an
early role for STAT3 in development. Tissue-specific knockouts have indicated roles for STAT3
in T cells (Takeda et al., 1998), macrophages (Takeda et al., 1999), mammary gland (Chapman
et al., 1999), liver (Alonzi et al., 2001), and skin (Sano et al., 1999).
STAT5 proteins were first identified as mammary gland factor (MGF), a protein from
mouse mammary gland that bound to the β-casein promoter (Schmitt-Ney et al., 1991). It was
subsequently determined that MGF was two closely related proteins, STAT5A and STAT5B
(Wakao et al., 1994), which are expressed in all tissues (Kisseleva et al., 2002). Transgenic
deletion of STAT5 resulted in defective prolactin-dependent mammary gland development but
also significantly reduced fat pad size (Teglund et al., 1998). Thus, although a major role for
STAT5 proteins is in the regulation of mammary tissue development, STAT5 proteins likely
modulate adipocyte function. During differentiation of 3T3-L1 adipocytes, expression levels of
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STAT5A and 5B were highly induced (Stewart et al., 1999). Moreover, ectopic expression of
STAT5A has been shown to confer adipogenesis in two different nonprecursor cell lines (Floyd
and Stephens, 2003).
STAT6 is ubiquitously expressed and has a role in acquired immunity. The STAT6
knockout mouse exhibited lower numbers of Th2 cells and a failure of IL-4 to induce expression
of major histocompatibility factor II, IL-4 receptor or immunoglobulin E receptor (Kaplan et al.,
1996).
STAT action may be regulated at the level of the receptor, JAK or STAT. Modification
of STATs is a mechanism of regulation; in addition to the phosphorylation of tyrosine, STATs
may be dephosphorylated, serine phosphorylated, ubiquitylated, acetylated, methylated, or
SUMOylated (Kisseleva et al., 2002). Furthermore, STATs 1, 3, 5A, 5B, and 6 are naturally
expressed as splice variants or are proteolytically cleaved to produce truncations that likely
function as dominant negative regulators of STATs (Kisseleva et al., 2002).
SHP1 and 2 are phosphatases that negatively regulate JAK activity and are constitutively
expressed proteins that have been shown to negatively regulate cytokine signaling (Kisseleva et
al., 2002). These phosphatases have SH2 domains which are likely involved in recruitment to
the phosphorylated receptor or JAK. Another phosphatase identified as a regulator of
JAK/STAT signaling is CD45, a membrane spanning protein with a well-characterized role in T
cell signaling (Alexander et al., 2000). In addition, protein tyrosine phosphatase-εC, is induced
by cytokines and dephosphorylates a JAK to specifically downregulate STAT3 signaling
(Tanuma et al., 2000).
Members of the suppressors of cytokine signaling (SOCS) family are induced by STATs
and directly interact with STATs to attenuate signaling in a negative feedback loop (reviewed in

17

Krebs and Hilton, 2001). SOCS proteins are rapidly induced upon cytokine stimulation and
STAT activation. There are eight members of the family, cytokine-inducible SH2 protein (CIS)
and SOCS 1-7, which contain two consensus elements, an SH2 domain and a C-terminal SOCS
box, in addition to an N-terminal variable region. The SOCS box is a common motif among
more than 40 proteins, the majority of which have unknown functions, although it has been
hypothesized that the SOCS box could function as an adapter for E3 ubiquitin ligases (Kile et al.,
2002). SOCS proteins may regulate cytokine signaling by multiple mechanisms. SOCS-1 has
been shown to interact with JAKs via the activation loop blocking ATP binding, and thus,
inhibiting catalytic activity (Nicholson et al., 1999). SOCS-3 has been found to bind receptors
without inhibiting JAK kinase activity (Nicholson et al., 1999). CIS also binds to receptors and
prevents recruitment of STATs (Yoshimura et al., 1995).
Another family of proteins that negatively regulate STATs is the protein inhibitors of
activated STAT (PIAS) proteins, which are constitutively expressed. Five PIAS proteins have
been identified: PIAS1, an inhibitor of STAT1 (Liao et al., 2000); PIAS3, an inhibitor of STAT3
(Chung et al., 1997); PIASxα and PIASxβ, regulators of androgen receptor, as well as
TGFβ/Smad signaling (Kotaja et al., 2000, Ohshima and Shimotohno, 2003), and PIASy (Liu et
al., 2001). PIAS 1, 3, x and y have been implicated as small ubiquitin like molecule-1 (SUMO1) tethering proteins and likely act to bring SUMOylation targets in proximity to the SUMO
conjugase, ubc9 (Kotaja et al., 2002). SUMOylation of transcription factors results in activation
of some, regulation of others and altered cellular localization (Eloranta et al., 2002). The
specific mechanisms for these effects are not yet known. STAT1 has recently been demonstrated
to be a substrate for PIASxα-mediated SUMOylation (Rogers et al., 2003).
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STATs have important roles in responses to stress, particularly immune responses. An
important area of research is identifying targets of transcriptional modulation by STATs,
particularly within the context of cooperativity with other transcription factors. There is also
much to be understood of the crosstalk between signaling pathways. Elucidation of STAT
function will be an important facet of cytokine signaling. Characterizing STAT activity and
interactions with other proteins could yield solutions to human diseases.
STATs were first implicated in energy balance with the finding that the adipocytesynthesized hormone leptin activates STATs 3, 5 and 6 in the hypothalamus (Tartaglia et al.,
1995, Ghillardi et al., 1996). Furthermore, the discovery that STATs 1, 3, 5A, 5B, and 6 are
expressed in adipocytes has implicated STAT proteins as regulators of adipocyte function
(Stephens et al., 1996). STATs 1, 5A, and 5B are highly induced during differentiation;
moreover, disregulation of adipogenesis attenuates induction of these STATs (Stewart et al.,
1999). In the agouti mouse model of obesity the expression of STATs 1 and 3 are upregulated
(Mynatt and Stephens, 2001). Furthermore, ectopic expression of STAT5A in nonprecursor cells
confers the ability to differentiate into fat cells (Floyd and Stephens, 2003). Hence, STAT
proteins may modulate multiple aspects of adipocyte biology and the expression of adipocyte
proteins.
1.4 Cytokines
IFNγ
Interferon-γ (IFNγ) is a cytokine that is primarily known for its roles in immunological
responses but has also been shown to affect fat metabolism and adipocyte gene expression. In
adipocytes, IFNγ treatment results in decreased lipoprotein lipase activity (LPL) and increased
rate of lipolysis (Doerrler et al., 1994). In 3T3-F442A adipocytes, exposure to IFNγ results in
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decreased expression of LPL and FAS. Also, in various rodent preadipocyte cell lines, IFNγ
inhibits the differentiation of preadipocytes (Grossberg and Keay, 1980; Keay and Grossberg,
1980; Gregoire et al., 1992). Acute IFNγ treatment of cultured and native rat adipocytes results
in a dose- and time-dependent activation of STATs 1 and 3 (Stephens et al., 1998). Moreover,
studies have linked IFNγ and insulin resistance during viral infections (Koivisto et al., 1989;
Khanna et al., 1999). IFNγ therapy of cancer patients has been associated with the development
of hyperglycemia (Shiba et al., 1998).
LIF
Leukemia inhibitory factor (LIF) is a member of the gp130 cytokine family, cytokines
which are unrelated by sequence, but are structurally similar and share a common receptor,
gp130 (Robinson et al., 1994, Kishimoto et al., 1995). LIF has pleiotropic actions which include
maintaining totipotency of embryonic stem cells (Williams et al., 1988), enhancing survival of
peripheral neurons (Murphy et al. 1991) and oligodendrocytes (Butzkueven et al., 2002), and
promoting bone formation (Dazai et al., 2000). LIF also has multiple effects on adipocytes and
adipose tissue. Initially, LIF was characterized as an inducer of wasting weight loss in mice
engrafted with a melanoma cell line that overproduces LIF (Mori et al., 1989). Subsequently,
LIF was found to inhibit lipoprotein lipase (LPL) expression and activity in 3T3-L1 and 3T3F442A adipocytes but does not affect the rate of lipogenesis (Marshall et al., 1994). In addition,
adipogenic effects of LIF have been indicated by enhanced activity of glycerol-phosphate
dehydrogenase and accumulation of lipid in Ob1771 cells during adipogenesis (Aubert et al.,
1999). However, other findings have indicated that LIF prevents adipogenesis in bone marrow
stromal cells (Gimble et al., 1994). Thus, it is likely that the effects of LIF on adipocytes vary
with the developmental stage of the cells or tissue.
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CT-1
Cardiotrophin-1 (CT-1) is also a member of the gp130 cytokines. Cytokines in the gp130
family exhibit functional redundancy as they signal through shared receptor components
(Kishimoto et al. 1995). Like LIF, CT-1, ciliary neurotrophic factor (CNTF), and oncostatin M
(OSM) bind the LIF receptor (LIFR), in addition to the common receptor, gp130 (Baumann et al.
1993, Wollert et al. 1996). Because these cytokines signal through common elements that are
ubiquitously expressed, many of their effects are similar in various tissues. CT-1 was cloned
from a cDNA library of embryoid bodies screened for clones that were capable of inducing
cardiomyocyte hypertrophy (Pennica et al., 1995). The clone encoded a novel 21.5 kD protein,
which activated morphological and molecular markers of a hypertrophic response in culture, but
also had cardioprotective effects (Pennica et al., 1995; Sheng et al., 1996). It promoted the
growth of myocytes in length and the serial organization of sarcomeres, the same effects
observed with ventricular volume overload (Wollert et al., 1996). Moreover, the genes activated
by CT-1 administration appeared to be a reactivation of the pattern of gene expression of the
developing heart (Wollert et al., 1996). CT-1 effects parallel those of LIF in the heart and other
tissues. Treatment with CT-1 in vitro inhibits growth of mouse myeloid leukemic M1 cells,
modulates sympathetic neuron transmitter phenotype, inhibits differentiation of embryonic stem
cells, and induces acute phase protein expression in hepatocytes (Pennica et al., 1995; 1996,
Peters et al., 1995). Since the expression of LIFR and gp130 are ubiquitous, the specificity of
the targets may be defined by the expression of CT-1 and LIF (Ip et al., 1993). LIF is expressed
at low levels in adult tissues (Robertson et al., 1993); however, CT-1 is highly expressed in
many tissues in adults and thus, there are likely pleiotropic effects in vitro and in vivo (Pennica et
al., 1995; 1996; Ishikawa et al., 1996).
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PRL
Prolactin (PRL) is a peptide hormone primarily known for its role in mammary gland
development during lactation, but it has been shown to have pleiotropic effects in a variety of
tissues (Bole-Feysot et al., 1998). PRL activates multiple signal transduction pathways,
including MAPK (Avruch et al., 1994) and phosphatidylinositol-3 kinase (Bailey et al., 2004);
however, the JAK/STAT pathway is the predominant signaling cascade activated by PRL. The
PRL receptor (PRL-R) dimerizes upon binding by PRL, activating an associated JAK. The
regulation of mammary tissue by PRL is well-characterized, but there is evidence of a role in
adipose tissue. PRL-R is expressed in both mouse (Ling et al., 2000) and human adipose tissue
(Ling et al., 2003) and is induced during adipogenesis of bone marrow stromal cells (McAveney
et al., 1996). In addition, ectopic expression of the PRL-R in NIH-3T3 cells resulted in efficient
adipocyte conversion and activation of the aP2 promoter in a PRL-dependent manner (NanbuWakao et al., 2000). Taken together, these observations strongly suggest a role for PRL in the
modulation of adipocyte function. Furthermore, the occurrence of obesity has been correlated
with hyperprolactinomas (Greenman et al., 1998). In opposition to these adipogenic effects,
PRL has been shown to induce lipolysis in rabbits (Fortun-Lamothe et al., 1996) and mouse
adipose tissue explants (Fielder and Talamantes, 1987). In addition, studies have shown that
PRL reduces LPL activity in cultured human adipocytes (Ling et al., 2003), and the activity of
LPL and FAS in adipose tissue of lactating mice (Flint et al., 1981). Thus, PRL exerts
adipogenic and anti-lipogenic effects on adipose tissue.
1.5 Rationale
Five members of the STAT transcription factor family are expressed in adipocytes;
STATs 1, 5A, and 5B are highly induced during adipogenesis, and STATs 3 and 6 are expressed
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in preadipocytes and adipocytes (Stephens et al., 1996; Stewart et al., 1999). STAT5A promotes
adipogenesis in nonprecursor cells, and thus STAT5A may be a component of the transcriptional
cascade governing adipogenesis (Floyd and Stephens, 2003). However, a function for STAT
proteins is not known in adipocytes. The identification of transcriptional targets of STATs will
provide some insight into the function of STATs in mature adipocytes. Thus, we have
characterized STAT binding sites in the promoters of genes which are regulated by STATactivating cytokines. STAT binding sites have been found in the promoters of PPARγ2, LPL,
FAS and C/EBPδ, suggesting that the expression of these genes is modulated by STATs in vivo.
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CHAPTER 2: EXPERIMENTAL PROCEDURES
2.1 Materials
Dulbecco’s modified Eagle medium (DMEM), fetal bovine serum (FBS), and leukemia
inhibitory factor (LIF) were purchased from Invitrogen. Murine interferon-γ (IFNγ) was
purchased from Boehringer Mannheim. Fetal bovine serum (FBS) was purchased from Atlanta
Biologicals, and calf serum was purchased from Biosource. Bovine serum, actinomycin D,
cycloheximide, and GH were purchased from Sigma. Foxo1, STAT1, STAT3, and highly
phospho-specific STAT5 (Tyr694) antibodies were purchased from Upstate Biotechnology;
STAT3, STAT5A, PPARγ, and SREBP1 antibodies were purchased from Santa Cruz; STAT3,
highly phospho-specific STAT3 (Tyr705), STAT 5 (Y694), JAK1(p-Y) and JAK2(p-Y) antibodies,
and FAS antibody were purchased from BD transduction laboratories. LPL antibody was
purchased from Research Diagnostics, Inc, and highly phospho-specific STAT1 (Tyr701) was
purchased from Biosource. [α-32P] dCTP and [α-32P] dATP were both purchased from PerkinElmer and Amersham Biosciences. Deoxynucleotide thymine triphosphate, dATP, and dGTP
were purchased from Amersham Biosciences. DNA polymerase I large (Klenow) fragment and
U0126 were purchased from Promega. Oligonucleotides were purchased from Integrated DNA
Technologies.
2.2 Cell Culture
Murine 3T3-L1 preadipocytes were plated and grown to 2 days post-confluence in
DMEM containing 10% bovine serum. Medium was changed every 48 h. Cells were induced to
differentiate by changing the medium to DMEM containing 10% FBS, 0.5 mM 3-isobutylmethylxanthine, 1 µM dexamethasone, and 1.7 µM insulin (MDI). After 48 h, this medium was
replaced with DMEM supplemented with 10% FBS, and the cells were maintained in this
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medium until utilized for experimentation. The adipocyte phenotype was attained following 120
hours of differentiation.
2.3 Preparation of Whole Cell Extracts
Cell monolayers were rinsed with PBS and then harvested in a nondenaturing buffer
containing 10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100,
0.5% Nonidet P-40, 1 µM phenylmethylsulfonyl fluoride, 1 µM pepstatin, 50 trypsin inhibitory
milliunits of aprotinin, 10 µM leupeptin, and 2 mM sodium vanadate. Samples were extracted
for 30 min on ice and centrifuged at 15,000 rpm at 4oC for 15 min. Supernatants containing
whole cell extracts were analyzed for protein content by BCA analysis (Pierce) according to the
manufacturer’s instructions.
2.4 Preparation of Nuclear and Cytosolic Extracts
Cell monolayers were rinsed with PBS and then harvested in a nuclear homogenization
buffer (NHB) containing 20 mM Tris (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 5 µM dithiothreitol,
1 µM phenylmethylsulfonyl fluoride, 1 µM pepstatin, 50 trypsin inhibitory milliunits of
aprotinin, 10 µM leupeptin, and 2 mM sodium vanadate. Igepal CA-630 (Nonidet P-40) was
added to a final concentration of 0.15%, and cells were homogenized with 16 strokes in a
Dounce homogenizer. The homogenates were centrifuged at 1500 rpm for 5 min. Supernatants
were saved as cytosolic extract, and the nuclear pellets were resuspended in 1/2 volume of NHB
and were centrifuged as before. The pellet of intact nuclei was resuspended again in 1/2 of the
original volume of NHB and centrifuged again. The majority of the pellet (intact nuclei) was
resuspended in an extraction buffer containing 20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 5 µM dithiothreitol, 1 µM phenylmethylsulfonyl fluoride, 1 µM
pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 µM leupeptin, 2 mM sodium vanadate,
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and 25% glycerol. Nuclei were extracted for 30 min on ice. The samples were subjected to
centrifugation at 10,000 rpm at 4oC for 10 min. Supernatants containing nuclear extracts were
analyzed for protein content, using a BCA protein assay kit (Pierce).
2.5 Gel Electrophoresis
Proteins were separated in 7.5% polyacrylamide (National Diagnostics) gels containing
sodium dodecyl sulfate (SDS) according to Laemmli (1970) and transferred to nitrocellulose
(Bio-Rad) in 25 mM Tris, 192 mM glycine, and 20% methanol. Following transfer, the
membrane was blocked in 4% milk overnight at 4oC. Results were visualized with horseradish
peroxidase (HRP)-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories) and
enhanced chemiluminescence (Pierce).
2.6 RNA Analysis
Total RNA was isolated from cell monolayers with Trizol (Invitrogen) according to
manufacturer’s instructions with minor modifications. For Northern blot analysis, 15 µg of total
RNA was denatured in formamide and electrophoresed through a formaldehyde/agarose gel.
The RNA was transferred to Zeta Probe-GT (Bio-Rad), cross-linked, hybridized, and washed as
previously described (Stephens and Pekala, 1992). The blots for FAS were transferred in a
buffer containing 75 mM sodium citrate tribasic, 10 mM NaOH and 750 mM NaCl. Probes were
labeled by random priming using Klenow fragment and [α-32P] dCTP or using Strip-EZ DNA
(Ambion) and [α-32P] dATP according to manufacturer’s instructions to generate probes that
were easily removed from the membrane.
2.7 Electrophoretic Mobility Shift Assay
Double-stranded oligonucleotides were 3’-end labeled with 20 µCi [32P] (400-800
Ci/mmol) dCTP and Klenow fragment. End-labeled oligonucleotides were purified using a
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Microspin G-25 column, according to manufacturer’s instructions (Amersham Biosciences).
Specific activity of the oligonucleotides was determined by scintillation counting. Nuclear
extracts were incubated with the end-labeled oligonucleotides (50,000 cpm/µL) for 30 min on ice
in a binding buffer containing 15 µM EDTA, 40 mM KCl, 3.75 mM Hepes, 5 mM MgCl2, 1.2%
Ficoll, and 3 µg poly dIdC (Amersham Biosciences), as previously described by Ritzenthaler and
colleagues (1991). The samples were loaded on a pre-run (1 h, 100 V at 4oC) 6% acrylamide/
bisacrylamide TBE gel containing 90 mM Tris, 90 mM boric acid, and 2 mM EDTA, pH 8.0.
For supershift analysis, nuclear extracts were preincubated with 4 µg of antibody for 1 h at room
temperature. For cold competition, nuclear extracts were incubated with unlabeled
oligonucleotide for 15 min on ice prior to incubation with the labeled probe. The gels were run
at 20 mA for approximately 2 h. The gels were dried at 80oC for 1 h under a vacuum and then
exposed to Kodak BioMax MS film with a Kodak BioMax high energy intensifying screen.
2.8 Constructs
The PPARγ2 promoter (-609 to +52)/luciferase reporter contruct and C/EBPα expression
construct were generous gifts from Dr. Jeffrey Gimble. The rat FAS promoter (-250 to
+65)/luciferase construct was generously provided by Dr. Steven Clarke. The rat FAS promoter
(-1594 to +65)/luciferase and (-700 to +65)/luciferase constructs were generously provided by
Dr. Peter Tontonoz. The PPARγ2 promoter (-609 to +65)/luciferase construct and the FAS (1594 to +65)/luciferase construct were mutated at positions -217 and -212, and -901 and -902,
respectively, within the STAT binding sites using the QuikChange Site Directed Mutagenesis
Kit, according to manufacturer’s instructions (Stratagene). The following oligonucleotide and
corresponding anti-sense oligonucleotide were used to alter the STAT binding site with the
altered bases underlined: PPARγ/GAC AAT GTA GCA ACG TTC TCC TCG TAA TGT ACC
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AAG TC and FAS/GGG AGG GTG AGG GTC AAG GAA ACC AGC AAC TCA GG.
Sequence analysis was performed to confirm the presence of the mutated bases using Big Dye
Terminator Extension Reaction (ABI Prism). The minimum promoter thymidine kinase (TK)
renilla vector was purchased from Promega.
2.9 Transient Transfections
3T3-L1 preadipocytes were transiently cotransfected with the various promoter
constructs and the TK/renilla vector or SV40/β-galactosidase construct to control for transfection
efficiency, as previously described (Hogan and Stephens, 2001; Zvonic et al., 2004), using
FuGENE 6 (Roche Molecular Biochemicals) or Polyfect (Qiagen) according to manufacturer’s
instructions. Cell lysates were analyzed for firefly and renilla luciferase activity or βgalactosidase activity using the Dual Luciferase Reporter Assay System or the Luciferase Assay
System and the β-galactosidase Enzyme System (Promega). Relative light units (RLU) were
determined by dividing firefly luciferase activity by renilla luciferase activity or β-galactosidase
activity. Results are given as +/- standard deviation.
2.9 Determination of [H3]2-Deoxyglucose Uptake
The assay of [3H]2-deoxyglucose was performed as previously described (Stephens and
Pekala, 1991). Briefly, mature 3T3-L1 adipocytes were serum deprived for 4 h and then
incubated in the presence or absence of insulin (44 nM). Glucose uptake was initiated by
addition of [3H]2-deoxyglucose at a concentration of 0.1 mM 2-deoxyglucose in 1 µCi of [3H]2deoxyglucose in Krebs-Ringer-Hepes buffer. Glucose uptake is reported as [3H] radioactivity,
corrected for nonspecific diffusion and normalized to total protein content as determined by
BCA analysis. Uptake measurements were performed in triplicate under conditions where
hexose uptake was linear.
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CHAPTER 3: IDENTIFICATION AND CHARACTERIZATION OF A STAT1 BINDING
SITE IN THE PEROXISOME PROLIFERATOR-ACTVIATED RECEPTORγ2
PROMOTER*§
3.1 Introduction
Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear
hormone receptor family and exists as four isoforms, three of which are known to be highly
expressed in adipocytes (Zhu et al., 1995; Fajas et al., 1998; Sundvold et al., 2001). PPARγ is a
transcription factor which governs adipogenesis, modulates systemic insulin sensitivity, and
contributes to energy metabolism (Tontonoz et al., 1994b; Lehmann et al., 1995; He et al.,
2003). Interferon-γ (IFNγ) decreases PPARγ expression by targeting PPARγ to the proteasome
for degradation and blocking synthesis of PPARγ in a manner that is independent of new protein
synthesis (Waite et al., 2001). IFNγ is a cytokine with anti-adipogenic effects and stimulates
lipolysis in mature cultured adipocytes (Keay and Grossberg, 1980; Grossberg and Keay, 1980;
Gregoire et al., 1992; Doerrler et al., 1994). Since IFNγ is a potent activator of signal
transducers and activators of transcription (STATs) 1 and 3 in adipocytes (Stephens et al., 1998),
we have hypothesized that IFNγ-activated STATs negatively regulate the transcription of
PPARγ.
In this investigation, we have identified a site in the PPARγ2 promoter that is responsive
to IFNγ treatment and is bound by STAT1. In a recent study, it was demonstrated that
cardiotrophin-1 (CT-1), a gp130 cytokine, transiently downregulated expression of PPARγ in
* Reprinted from Biochemical and Biophysical Research Communications, 287, Hogan JC and
Stephens JM, The identification and characterization of a STAT 1 binding site in the PPARγ2
promoter, 484-492, 2001, with permission from Elsevier.
§ Reprinted from Journal of Biological Chemistry, 279, Zvonic et al., Effects of cardiotrophin-1
(CT-1) on adipocytes, 47572-47579, 2004, with permission from ASBMB.
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3T3-L1 adipocytes (Zvonic et al., 2004). Therefore, we have also investigated the ability of two
gp130 cytokines, leukemia inhibitory factor (LIF) and CT-1, to stimulate binding by STAT
proteins to this site in the PPARγ2 promoter. Although both LIF and CT-1 stimulate binding by
STAT1 to the site in the PPARγ2 promoter, LIF did not affect PPARγ mRNA levels. These
studies demonstrate that the PPARγ2 promoter contains a highly specific STAT1 binding site
and we propose that the repression of PPARγ transcription induced by IFNγ and CT-1 is
mediated by STAT1 homodimers.
3.2 Results
Our recent studies demonstrated that acute IFNγ treatment of adipocytes resulted in a
repression of PPARγ transcription that was independent of new proteins synthesis (Waite et al.,
2001). Therefore, we examined the PPARγ promoter sequences currently available in GenBank
for IFNγ responsive elements. We focused our search on IFNγ-activated sequence (GAS)/STAT
induced element (SIE)-like elements (TTCNNNGAA) that are known to mediate IFNγ-sensitive
regulation in a STAT-dependent manner (Shuai et al., 1992; Khan et al., 1993). As shown in
Table 3.1, our analysis revealed three putative elements in the PPARγ2 promoter that resembled
GAS elements.
Table 3.1 Potential STAT binding sites in the PPARγ2 promoter
Gene
Position
Sequence
Consensus GAS/SIE
TTC NNN GAA
PPARγ2
-107 to -95
T TTC TGT GTT TAT
PPARγ2
-423 to -412
T TTG GCC AAA TA
PPARγ2
-221 to -207 C GTT TTC CTT GTA AT
PPARγ2
mutant -221 C GTT CTC CTC GTA AT

IFNγ Responsive
No
No
Yes
No

Electrophoretic mobility shift assays (EMSAs) were performed with these labeled sites
and extracts isolated from 3T3-L1 adipocytes that were untreated or exposed to an IFNγ

30

treatment for 15 min. The responsiveness of these sites to IFNγ was examined by EMSA by
using cytosolic and nuclear extracts. As shown in Fig 3.1, the -221 to -207 site of the PPARγ2
promoter was bound by two protein complexes which we classified as Shift #1 and Shift #2.
Notably, this site was only shifted by nuclear proteins and not by cytosolic proteins. Moreover,
Shift #1 was highly responsive to IFNγ treatment. The free unbound probe is not shown in the
figure. The other GAS-like elements we identified in the PPARγ2 promoter at -423 to -412 and
-107 to -95 were not shown to be responsive to IFNγ treatment (Fig 3.1).
nuc
− + IFNγ

nuc
− + IFNγ

cyto nuc
− + − + IFNγ
Shift #1

Shift #2
-423 to -412

-107 to -95

-221 to -207

Figure 3.1 The identification of an IFNγ-sensitive element in the PPARγ2 promoter.
Cytosolic and nuclear extracts were prepared form 3T3-L1 adipocytes that were untreated (-) or
treated (+) for 15 min with IFNγ. The extracts were incubated with the 32P-labeled
oligonucleotide of the -221 to -207 site of the PPARγ2 promoter for analysis by EMSA. This is
a representative experiment independently performed three times.
The specificity of binding to this site was demonstrated by the use of cold competitor and
mutant oligonucleotides. The binding of nuclear extracts to radiolabeled -221 to -207 site was
successively competed with increasing concentrations (400 pg/µl to 1µg/µl) of cold competitor
(Fig 3.2A and Fig 3.2B). The specificity of both Shift #1 and Shift #2 is indicated with the use
of cold competitor. However, a sequence which also resembled the consensus GAS element,
-107 to -95 of the PPARγ2 promoter, did not compete the binding by the protein complex to the
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labeled -221 to -207 site (Fig. 3.2B). Also, a mutant -221 to -207 sequence (Table 1) did not
compete for binding to Shift #1, but it did reduce some of the binding to Shift #2.
To assess whether STAT proteins were components of the protein complexes that bind to
the PPARγ2 promoter following IFNγ treatment, we performed supershift analysis. Prior to
EMSA analysis, nuclear extracts were incubated with antibodies directed against STATs 1, 3, or
5A. We investigated the binding of these three STATs because they are the only STATs present
in the nucleus under these conditions. As shown in Fig 3.2A, the STAT1 antibody completely
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Figure 3.2 Binding to the -221 to -207 site of the PPARγ2 promoter is specific. (A) Nuclear
extracts were prepared from 3T3-L1 adipocytes that were untreated (-) or treated (+) with
IFNγ for 15 min. The extracts were preincubated with varying concentrations of unlabeled -221
to -207 oligonucleotide (3.6 nM to 8.9 µM). The nuclear extracts were then incubated with the
labeled probe. (B) Nuclear extracts from IFNγ-treated 3T3-L1 adipocytes were preincubated
with unlabeled oligonucleotides (8.9 µM) of the -221 to -207 or the -107 to -95 sites of the
PPARγ2 promoter or with the mutant -221 to -207 site. The nuclear extracts were then incubated
with the labeled -221 to -207 probe and subjected to EMSA. This is a representative experiment
independently performed two times.
supershifted Shift #1, but had no effect on Shift #2. Moreover, antibodies to either STAT 3 or
5A did not supershift Shift #1. As shown in Fig 3.3B, a time course analysis revealed that
binding to Shift #2 was not responsive to IFNγ (as also indicated in Figs 3.1 and 3.2), but the
binding to Shift #1 was regulated by IFNγ in a time-dependent manner. Following a 15-minute
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or two-hour stimulation with IFNγ, STAT1 binds to the -221 to -207 sequence. Yet after a fourhour stimulation with IFNγ, the binding by STAT1 is greatly reduced. Also, the binding to Shift
#1 correlates with the presence of STAT1 in the nucleus (data not shown).
A
Free

−

+

STAT1
− +

STAT3 STAT5A Antibody
−
− +
+ IFNγ
Shift #1

Shift #2

B
.25 2

4

STAT1
.25 2 4

Antibody
IFNγ (hours)

Shift #1

Shift #2

Figure 3.3 STAT1 binds to the PPARγ2 promoter in vitro. (A) Nuclear extracts were
prepared from 3T3-L1 adipocytes that were untreated (-) or treated (+) with IFNγ for 15 min.
For supershift analysis, the nuclear extracts were preincubated with antibodies (4 µg) for STAT1,
3 or 5A prior to incubation with the 32P-labeled -221 to -207 oligonucleotide. (B) Nuclear
extracts were prepared from 3T3-L1 adipocytes that were treated with IFNγ for the various times
indicated. The extracts were incubated with the -221 to -207 radiolabeled probe for EMSA
analysis. Supershift analysis was performed by preincubating the nuclear extracts with a STAT1
antibody (4 µg). This is a representative experiment independently performed two times.
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To determine if this region of the PPARγ2 promoter containing the STAT1 site (-221 to
-207) was sensitive to IFNγ regulation, we obtained a luciferase reporter construct with -609 to
+52 base pairs of the PPARγ2 promoter. This construct was transiently transfected into both
NIH 3T3 cells and 3T3-L1 cells. In each experiment, cells were cotransfected with an SV40/βgalactosidase vector to control for transfection efficiency. However, the NIH 3T3 cells were also
cotransfected with a C/EBPα expression in order to activate the PPARγ2 promoter through the
C/EBP recognition site at -340 to -327 (Clarke et al., 1997). As previously reported (Clarke et
al., 1997), cotransfection with the C/EBPα expression construct resulted in a substantial increase
in luciferase activity compared to transfection of the PPARγ2 promoter (-609 to +52)/luciferase
reporter construct alone (data not shown). As shown in Fig 3.4A, treatment of the cotransfected
NIH 3T3 cells with IFNγ for two or 24 hours resulted in a discernable reduction in luciferase
activity compared to untreated cotransfected NIH 3T3 cells when normalized to β-galactosidase
activity. We also performed transient transfections with the PPARγ2 reporter construct in 3T3L1 cells. The 3T3-L1 cells were transfected with the PPARγ2 promoter (-609 to +52)/luciferase
reporter construct 24 hours after removal of the differentiation cocktail. As shown in Fig 3.4B,
treatment with IFNγ for two hours resulted in substantial reduction in luciferase activity
compared with the untreated transfected 3T3-L1 cells (Fig 3.4B). After 24 hours, basal levels of
the reporter expression did not change, but there was still a detectable decrease in PPARγ
promoter activity in the IFNγ-treated cells. Transfection of the 3T3-L1 cells at different times
after the induction of differentiation produced similar responses to IFNγ (data not shown). To
determine the functional significance of the -221 to -207 site of the PPARγ2 promoter, we
transfected 3T3-L1 cells with the wild type PPARγ2 promoter (-609 to +52)/luciferase construct
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Figure 3.4 IFNγ modulates the activity of the PPARγ2 promoter. (A) NIH-3T3 cells were
transiently transfected using FuGENE (Roche) with the PPARγ2 promoter (-609 to
+52)/luciferase reporter construct and with a plasmid expressing C/EBPα to increase levels of
reporter expression. Also, cells were transfected with the SV40/β-galactosidase vector to control
for transfection efficiency. Cells were treated with IFNγ for 2 h and 24 h before harvesting. Cell
lysates were analyzed for luciferase and β-galactosidase activity. Relative light units (RLU)
were determined by dividing luciferase activity by β-galactosidase activity. Results are shown as
+/- standard deviation. (B) 3T3-L1 cells were treated with the MDI cocktail for 48 h and then
were placed in DMEM with 10% FBS for 8 h. The cells were transiently transfected with the
PPARγ2 promoter (-609 to +52)/luciferase reporter and SV40/β-galactosidase constructs. The
cells were then treated with IFNγ for 2 or 24 h. RLU was determined as described above. (C)
3T3-L1 preadipocytes were transiently transfected with the PPARγ2 promoter (-609 to
+52)/luciferase reporter or the mutant PPARγ2 m217/212 (-609 to +52)/luciferase reporter and
the SV40/β-galactosidase vector. Cells were untreated (-) or treated (+) with IFNγ for 2 h. RLU
was determined as described above.
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or the mutant PPARγ2 m217/212 promoter (-609 to +52)/luciferase construct which was altered
at two positions within the potential STAT1 binding site. A two hour treatment with IFNγ
decreased luciferase activity by 40% in cells transfected with the wild type construct, as shown
in Fig 3.4C. However, IFNγ treatment did not decrease the luciferase activity in cells transfected
with the mutant PPARγ2 m217/212 construct (Fig 3.4C), but IFNγ treatment slightly increased
luciferase activity. Furthermore, the basal level of luciferase activity of the mutant construct was
lower, indicating that the nucleotides that were mutated (217/212) may contribute to the basal
activity of the promoter.
These results suggested that modulation of PPARγ transcription by IFNγ could be
mediated by bases -221 to -207 of the PPARγ2 promoter, functioning as a STAT1 binding site.
Since some genes have been shown to be regulated by STAT1/STAT3 heterodimers, we
examined the ability of LIF, a potent activator of STAT3 in adipocytes (Stephens et al., 1998), to
induce binding to the IFNγ-sensitive element that we identified in the PPARγ2 promoter. As
shown in Fig 3.5A, treatment with LIF resulted in two mobility shifts that were effectively
competed with unlabeled probe. The intensity of these bands was substantially less than what we
observed following IFNγ treatment (Fig 3.1). Considerably less of the labeled probe was bound
by protein from LIF-treated extracts when compared to the amount of protein bound to the probe
from IFNγ treated extracts (data not shown). To determine if the protein-binding complex
contained STATs, the nuclear extracts were incubated with antibodies against STATs 1, 3, or
5A. Similar to IFNγ treatment, the STAT1 antibody was able to displace the LIF-regulated
protein binding to the -221 to -207 oligonucleotide (Fig 3.5B). However, the band that was
supershifted is very faint. Neither STAT3 nor STAT5A antibodies were capable of supershifting
this interaction. Hence, only STAT1 was capable of binding to this site of the PPARγ2 promoter
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following LIF stimulation but with substantially less binding to this site than that induced by
IFNγ, presumably due to the greatly reduced nuclear levels of activated STAT1. Therefore, we
examined the ability of LIF to regulate PPARγ mRNA levels. Fully differentiated 3T3-L1
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Figure 3.5 LIF-activated STAT1 binds the PPARγ2 promoter in vitro. (A) EMSA was
performed with nuclear extracts prepared from 3T3-L1 adipocytes untreated (-) or treated (+)
with LIF for 15 min. Nuclear extracts were incubated with the 32P-labeled -221 to -207
oligonucleotide. Cold competition was performed by preincubating the nuclear extracts with the
unlabeled oligonucleotide (8.9 µM). (B) Nuclear extracts from LIF-treated 3T3-L1 adipocytes
were preincubated with antibodies (4 µg) for STATs 1, 3, or 5A prior to incubation with the 32Plabeled -221 to -207 oligonucleotide. Protein-DNA complexes were resolved by EMSA. This is
a representative experiment independently performed three times.
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adipocytes were treated with either LIF or IFNγ and the expression of PPARγ mRNA levels was
examined by Northern blot analysis. As previously demonstrated, IFNγ treatment results in a
substantial decrease in PPARγ mRNA (Fig 3.6). Yet, exposure to LIF did not cause any
strikingchanges in PPARγ levels (Fig 3.6). In summary, these results suggest that the IFNγmediated repression of PPARγ transcription is modulated by STAT1 and not by STAT3 in
adipocytes. Moreover, LIF, an activator of STAT3 had no effect on PPARγ mRNA
accumulation.
IFNγ
0 .5 1 2 4

LIF
0 .5 1 2 4 Hours

1.8 kb

PPARγ

1.9 kb

β-actin

Figure 3.6 Acute LIF treatment does not affect the levels of PPARγ mRNA in adipocytes.
Total mRNA was isolated from fully differentiated 3T3-L1 adipocytes following treatment for
various times with IFNγ or LIF, as indicated. Twenty micrograms of total RNA was
electrophoresed, transferred to nylon, and subjected to Northern blot analysis. β-Actin indicates
that similar amounts of RNA were loaded for each sample. This is a representative experiment
independently performed two times.
Our recent studies demonstrated that treatment of 3T3-L1 adipocytes with CT-1 resulted
in a transient downregulation of PPARγ mRNA (Zvonic et al., 2004). Since CT-1 activates
STAT1 in adipocytes, we investigated the ability of CT-1-activated STAT proteins to bind the
-221 to -207 element of the PPARγ2 promoter. Therefore EMSAs were performed with nuclear
extracts from 3T3-L1 adipocytes acutely treated with CT-1 for 15 minutes. As shown in Fig
3.7A two protein complexes that shifted the -221 to -207 oligonucleotide were detected, but only
the slower-migrating protein complex was induced with CT-1 treatment in a dose-dependent
manner. In order to determine whether the CT-1-induced protein complex contained STAT
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proteins, supershift analysis was performed, using antibodies for STATs 1, 3, and 5A because
these are the STATs activated by CT-1 in adipocytes. The STAT1 antibody fully supershifted
the CT-1 induced protein complex; however the STAT3 and STAT5A antibodies had no effect
on the mobility of the protein complex, as shown in Fig 3.7B, indicating that the protein complex
may contain a STAT1 homodimer. Specificity of binding to the labeled oligonucleotide is
shown in Fig 3.7C. Binding of the CT-1-activated protein complex to the radiolabeled -221 to
-207 probe was competed with an excess of the unlabeled wild type oligonucleotide but not with
a mutant oligonucleotide, nor with the -107 to -95 or the -431 to -408 oligonucleotides from the
PPARγ2 promoter. To assess the importance of this STAT1 site in the CT-1-induced modulation
of PPARγ, we transiently transfected 3T3-L1 preadipocytes with the wild type PPARγ2 promoter
(-609 to +52)/luciferase construct or with the mutant PPARγ2 m217/212 (-609 to +52)/luciferase
construct. The results in Fig 3.7D demonstrate that a six-hour treatment with CT-1 resulted in a
30% decrease in luciferase activity of the wild type construct. However, the basal luciferase
activity in cells transfected with the mutant PPARγ2 promoter construct was lower and was
moderately increased following CT-1 treatment, indicating that the mutated bases within the
STAT1 binding site are critical for the CT-1-induced downregulation of PPARγ.
3.3 Discussion
Each STAT family member shows a distinct pattern of activation by cytokines and upon
nuclear translocation, can regulate the transcription of particular genes in cell or tissue specific
manners (Darnell, 1997). Although adipocytes express STAT proteins and the expression of
three STAT family members is regulated during adipogenesis (Stephens et al., 1996), this is the
first study to identify an adipocyte target gene of activated STATs. In this investigation, we have
identified PPARγ2 as a negatively regulated gene target of STAT1. We demonstrated that
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Figure 3.7 CT-1 induces STAT1 binding to the -221 to -207 site of the PPARγ2 promoter in
vitro. (A) Nuclear extracts were prepared from 3T3-L1 adipocytes that were untreated (-) or
treated (+) with the indicated dose of CT-1 for 15 min. The extracts were incubated with the 32Plabeled -221 to -207 oligonucleotide for EMSA. (B) Nuclear extracts from CT-1-treated (0.3
nM) 3T3-L1 adipocytes were preincubated with antibodies for STATs 1, 3, or 5A for supershift
analysis. The extracts were then incubated with the radiolabeled -221 to -207 probe. (C) Prior to
incubation with the 32P-labeled -221 to -207 oligonucleotide, nuclear extracts from CT-1-treated
3T3-L1 adipocytes were preincubated with unlabeled oligonucleotides of the wild type and
mutant -221 to -207 site, and the -431 to -408 or the -107 to -95 sites from the PPARγ2 promoter.
(D) 3T3-L1 preadipocytes were transiently transfected using Polyfect (Qiagen) with either the
wild type PPARγ2 promoter (-609 to +52)/luciferase or the mutant PPARγ2 m217/212 (-609 to
+52)/luciferase reporter constructs, along with the TK/renilla construct to control for transfection
efficiency. After 48 hours, cells were untreated (-) or treated (+) with CT-1 for 6 h and then
harvested for analysis. Relative light units (RLU) were calculated by dividing luciferase activity
by renilla luciferase activity. Results are shown as +/- standard deviation.
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nuclear STAT1 was capable of specifically binding to the -221 to -207 sequence in the PPARγ2
promoter following stimulation by IFNγ, LIF, and CT-1. This interaction correlates with the
transcriptional repression of PPARγ2 by IFNγ and CT-1 that we previously reported (Waite et
al., 2001; Zvonic et al., 2004). Moreover, transfection of two different cell types with a PPARγ2

reporter construct that contains this STAT1 binding site was negatively regulated by IFNγ but
not when the site was mutated. These data strongly support our hypothesis that the IFNγ- and
CT-1-induced repression of PPARγ synthesis is mediated by STAT1. However, other studies
suggest that it is possible that other STAT1 binding sites are present in the PPARγ2 promoter.
For example, the p21 promoter has four distinct STAT1 binding sites (Chin et al., 1996).
Interestingly, we did not observe any effect of LIF, on PPARγ mRNA accumulation. The
activities of many promoters have been shown to be regulated by STAT1/STAT3 heterodimers.
However, the STAT1 site we identified in the PPARγ2 promoter is likely bound by a STAT1
homodimer. This is supported by our data demonstrating that LIF treatment only results in weak
binding to the PPARγ promoter and supershift analysis which clearly indicates that STATs 3 and
5A are not part of the DNA-binding complex. LIF, a gp130 cytokine, potently activates STAT3
but weakly activates STAT1 (Stephens et al., 1998) and does not regulate the expression of
PPARγ. Therefore, less STAT1 may be available in the nucleus to regulate transcription. Yet,
treatment with CT-1, another gp130 cytokine, resulted in a transient downregulation of PPARγ
expression. Thus, while activation of STAT1 may be a molecular event which results in
decreased PPARγ expression, it is also possible that other signaling cascades regulate the ability
of STAT1 to modulate PPARγ.
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Although STAT1 was originally identified as an activator of transcription, STAT1 has
also been found to act as a negative regulator of several genes in other cell types (Sharma et al.,
1998; Ikeda et al., 1999; Ramana et al., 2000). The negative transcriptional regulation can occur
by two mechanisms. First, STAT1 may activate the transcription of a second transcription factor
that acts as a negative regulator. Second, STAT1 could directly bind to the promoter of the
target gene and inhibit transcription. Our findings strongly suggest that the rapid IFNγ-induced
repression of PPARγ transcription and subsequent decrease in PPARγ mRNA is due to a direct
interaction of STAT1 with the PPARγ2 promoter. However, the IFNγ-induced decrease in
PPARγ transcription could be mediated in a STAT independent manner. Studies in STAT1 null
cells have demonstrated that some of the actions of IFNγ are independent of STAT1 (Gil et al.,
2001; Ramana et al., 2001). However, our observed regulation of PPARγ tightly correlates with
the presence of STAT1 in the nucleus and we have identified a highly specific STAT1 binding
site by utilizing EMSA analysis. In summary, these results strongly suggest that STAT1 acts as
a repressor of PPARγ2 transcription.
The quantity and activity of PPARγ in adipose tissue contributes to insulin sensitivity.
The PPARγ +/- mouse model is resistant to insulin resistance and to diet-induced obesity (Miles
et al., 2000). These findings suggest that protection from diseases such as type II diabetes and/or

obesity may be attained by the homeostatic balance of PPARγ expression and activity. One
mechanism of regulating PPARγ expression is via proteasomal mediated degradation that is
induced by both TZDs (Hauser et al., 2000) and IFNγ (Waite et al., 2001). However, PPARγ
expression can also be affected by changes in transcription and/or mRNA levels, which have
been shown to be regulated by TNFα, TZDs, and IFNγ (Rosenbaum & Greenberg, 1998; Waite
et al., 2001). Interestingly, the IFNγ-/CT-1 sensitive site we identified in the PPARγ2 promoter
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is not present in the PPARγ1 promoter. However, treatment with IFNγ results in a decrease in
both γ1 and γ2 proteins (Waite et al., 2001). Yet, the decay of the γ1 protein is much more rapid
that the decay of the γ2 protein. These results suggest that the regulation of PPARγ transcription
and degradation can be isoform specific. Although it is possible that the γ1 promoter is also
sensitive to transcriptional repression by IFNγ, we have been unsuccessful in our attempts to
identify an IFNγ-sensitive element in the γ1 promoter. To date, there is minimal information
about transcription factors that bind to the PPARγ promoters. A site that binds C/EBPα and
C/EBPδ has been identified in the PPARγ2 promoter that positively regulates PPARγ expression
(Clarke et al., 1997). In addition, the PPARγ1 and γ3 promoters both contain a consensus E-box
motif that has been shown to mediate the regulation of the PPARγ gene by ADD-1/SREBP-1 and
SREBP-2 (Fajas et al., 1999). Our studies have shown that the γ2 promoter contains a STAT1
binding site that likely mediates the IFNγ- and CT-1-induced repression of PPARγ2
transcription. In conclusion, there is very little known about the regulation of the PPARγ
promoters. The modulation of PPARγ synthesis by IFNγ, CT-1 and other cytokines may lead to
insights into the molecular mechanisms regulating energy homeostasis and may contribute to
understanding the defects underlying obesity and NIDDM.
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CHAPTER 4: STAT1 BINDS TO THE LIPOPROTEIN LIPASE PROMOTER IN
VITRO*
4.1 Introduction
Lipoprotein lipase (LPL) is an enzyme which catalyzes the hydrolysis of serum
triglycerides from very low density lipoproteins and chylomicrons for uptake of free fatty acids
and lipid storage in adipose tissue (Goldberg, 1996). Interferon-γ (IFNγ) has been shown to
decrease the expression and activity of LPL in cultured mouse and rat preadipocytes (Gregoire et
al., 1992) and in the 3T3-F442A adipocyte cell line (Feingold et al., 1992; Doerrler et al., 1994).
Since IFNγ activates the Janus kinase (JAK)/signal transducer and activator of transcription
(STAT) pathway in adipocytes, resulting in phosphorylation and nuclear translocation of STATs
1 and 3, we hypothesized that STATs directly regulated the expression of LPL in adipocytes. In
this study we have identified a STAT binding site in the promoter of the murine LPL gene.
Furthermore, we have demonstrated the binding of IFNγ-activated STAT1 to this site. Our
results suggest that STAT1 has a role in the regulation of LPL expression to modulate rate of
lipolysis in adipocytes.
4.2 Results
Previous studies have demonstrated that IFNγ treatment inhibits adipocyte differentiation
and decreases expression of LPL in adipocytes (Keay and Grossberg, 1980; Grossberg and Keay,
1980; Gregoire et al., 1992; Doerrler et al., 1994). Therefore, we examined the murine LPL
promoter sequence (GenBank M63335) for potential STAT binding sites. Our analysis revealed
two putative elements in the LPL promoter, shown in Table 4.1, which resembled the STAT
* Reprinted from Biochemical and Biophysical Research Communications, 307, Hogan JC and
Stephens JM, STAT1 binds to the LPL promoter in vitro, 350-354, 2003, with permission from
Elsevier.
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consensus IFNγ-activated sequence (GAS)/STAT induced element (SIE) sequence
(TTCNNNGAA).
Table 4.1 STAT1 binding sites in the LPL promoter
Gene
Position
Sequence
Consensus GAS/SIE
TTC NNN GAA
LPL
-125 to -108
CGT TTG CTC AAA TAT TT
LPL
-938 to -921 TG CTT TTC TAC AAA CAT G
LPL
mutant -938
TG CTT CTC TAC CAA CAT G

IFNγ Responsive
No
Yes
No

To analyze the binding of protein complexes to oligonucleotides corresponding to these
sequences of the LPL promoter, electrophoretic mobility shift assays (EMSAs) were performed
with nuclear extracts isolated from 3T3-L1 adipocytes that were unstimulated or treated for 15
min with IFNγ. As shown in Fig. 4.1A, the -938 to -921 site of the LPL promoter was bound by
two IFNγ-sensitive protein complexes indicated by the arrows. The binding of nuclear extracts
to the radiolabeled -938 to -921 site was successively competed with increasing concentrations
(7pg/µl to 40ng/µl) of cold competitor (Fig. 4.1A). Additional specificity of this interaction is
shown in Fig. 4.1B. The IFNγ-induced protein binding to a labeled oligonucleotide (-938 to
-921) of the LPL promoter (Lane 3) was effectively competed with an unlabeled wild-type
oligonucleotide (Lane 4), but not a mutant oligonucleotide (Lane 5). Interestingly, binding at
this site was also effectively competed with the STAT1 binding site that we previously identified
in the PPARγ2 promoter (Lane 6) (Hogan and Stephens, 2001). The other GAS-like element we
identified in the LPL promoter at -125 to -108 was unresponsive to IFNγ treatment (data not
shown).
As shown in the EMSA analysis in Fig 4.2A, the IFNγ-sensitive site was bound by
nuclear proteins. We did not observe binding by cytosolic proteins, but the lack of detectable
binding may be attributed to the apparent degradation of the probe, as less unbound probe
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Figure 4.1 The identification of a specific IFNγ-sensitive binding site in the LPL promoter.
(A) Nuclear extracts were prepared form 3T3-L1 adipocytes that were untreated (-) or treated (+)
for 15 min with IFNγ. The extracts were preincubated with increasing concentrations of
unlabeled -938 to -921 oligonucleotide (7 pg/µl to 40 ng/µl). The nuclear extracts were then
incubated with the labeled probe and subjected to EMSA. (B) Nuclear extracts from untreated
(-) or IFNγ-treated (+) 3T3-L1 adipocytes were preincubated with unlabeled oligonucleotides of
the -938 to -921 site of the LPL promoter, a mutant of the -938 to -921 site, or an oligonucleotide
from the PPARγ2 promoter which binds STAT1 proteins present in nuclear extracts of IFNγstimulated 3T3-L1 adipocytes. The nuclear extracts were then incubated with the labeled -938 to
-921 probe and subjected to EMSA.
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appeared at the bottom of the gel in lanes containing cytosolic protein than in lanes containing
nuclear protein. To determine if STAT1 was a constituent of the bound complexes, we
performed supershift analysis with a STAT1 antibody. Both of the IFNγ-sensitive protein
complexes were completely supershifted by the STAT1 antibody, as shown in Fig. 4.2A. We
also examined the effects of GH and LIF on the ability to induce binding to this site within the
LPL promoter. Our previous results demonstrate that LIF treatment can also result in STAT1
activation in 3T3-L1 adipocytes (Balhoff and Stephens, 1998) and GH can activate STAT5
proteins (Stephens et al., 1998). As shown in Fig. 4.2B, these results demonstrate that only
IFNγ, and not LIF or GH, can result in binding to the -938 to -921 site of the LPL promoter.
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Figure 4.2 IFNγ-activated STAT1 binds to the LPL promoter in vitro. (A) Cytosolic and
nuclear extracts were prepared from 3T3-L1 adipocytes that were untreated (-) or treated (+) with
IFNγ for 15 min. The extracts were incubated with 32P-labeled -938 to -921 oligonucleotide for
EMSA analysis. For supershift analysis, cytosolic and nuclear extracts were preincubated with a
STAT1 antibody. (B) Nuclear extracts from 3T3-L1 adipocytes, untreated (-) or treated (+) with
IFNγ, GH, or LIF, were incubated with the labeled -938 to -921 probe. Supershift analysis was
performed by preincubating the nuclear extracts with the STAT1 antibody (indicated as S1).
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Previous studies have clearly demonstrated that IFNγ treatment can result in an inhibition
of LPL transcription, mRNA and enzymatic activity. Our results demonstrate that IFNγactivated STAT1 can bind to the LPL promoter in vitro and may play a role in the repression of
LPL transcription. Hence, we investigated the ability of IFNγ to regulate LPL protein
expression. As shown in Fig. 4.3, IFNγ treatment of fully differentiated 3T3-L1 adipocytes
resulted in a notable decrease in LPL protein levels following 48 h of treatment.

0 6 12 24 36 48 IFNγ (hours)
95 kD

STAT5A

55 kD

LPL

Figure 4.3 IFNγ treatment decreases LPL protein levels. Whole cell extracts were prepared
from 3T3-L1 adipocytes following treatment with IFNγ for the various times indicated in the
figure. One hundred micrograms of each sample was resolved by SDS-PAGE and analyzed by
Western blot. The detection system was horseradish peroxidase and enhanced chemiluminescence (Pierce).
4.3 Discussion

Although IFNγ is primarily known for its roles in immunological responses, it has been
shown to have potent effects on adipocyte gene expression (Doerrler et al., 1994; Waite et al.,
2001) and to inhibit the differentiation of cultured rodent preadipocytes (Gregoire et al., 1992).
In adipocytes, IFNγ treatment results in decreased LPL activity and increased lipolysis (Doerrler
et al., 1994). In 3T3-F442A adipocytes, exposure to IFNγ results in decreased LPL and FAS

expression. Recent studies in macrophages have shown that IFNγ can inhibit LPL at the
transcriptional level (Hughes et al., 2002). Hence, the goal of our project was to identify IFNγsensitive sites within the LPL promoter.
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Our studies identified a region of the LPL promoter that binds two protein complexes in
an IFNγ-dependent manner. The specificity of binding to this site was demonstrated by the use
of cold competitor and mutant oligonucleotides (Fig. 4.1). Interestingly, binding to this site
within the LPL promoter was effectively competed with a STAT1 binding site that we previously
identified in the PPARγ2 promoter (Hogan and Stephens, 2001). Our previous studies
demonstrated that STAT1, but not STATs 3 or 5A, could bind to the -221 to -207 site of the
PPARγ2 promoter (Hogan and Stephens, 2001). These results suggested that both IFNγsensitive protein complexes that bind the LPL promoter in vitro contained phosphorylated
STAT1 proteins. This hypothesis is supported by our data demonstrating that the IFNγ-sensitive
element in the LPL promoter specifically binds nuclear, but not cytosolic, extracts isolated from
IFNγ-treated 3T3-L1 adipocytes (Fig. 4.2A). These results are further confirmed by supershift
analysis with STAT1 antibodies which revealed that both of these complexes contained STAT 1
proteins (Fig. 4.2). However, at this time, we do not know what proteins account for the
difference between the two IFNγ-sensitive STAT1 protein complexes that bind to the -938 to 921 region of the LPL promoter. We hypothesize that other adipocyte expressed STATs, in
particular, STAT3 and STAT5, are not part of these binding complexes. This hypothesis is
supported by our results which demonstrate that LIF, a potent STAT3 activator and GH, a potent
STAT5 activator, do not confer binding to this site (Fig. 4.2B). In addition, this effect appears to
be specific for IFNγ, since LIF treatment, which induces STAT1 phosphorylation and nuclear
translocation in these cells (Stephens et al., 1998), did not confer binding to this site. We predict
that the IFNγ-induced STAT1 binding to the LPL promoter plays a role in the IFNγ-mediated
repression of LPL transcription that has recently been observed (Hughes et al., 2002). In
addition, IFNγ has been previously shown to inhibit LPL mRNA and LPL activity. Our results
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demonstrating that IFNγ induced a decrease in LPL protein expression (Fig. 4.3) support these
studies. In summary, we have identified a STAT1 binding site within the murine LPL promoter
which likely plays a role in the IFNγ-induced decrease in LPL expression.
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CHAPTER 5: REGULATION OF FATTY ACID SYNTHASE BY STAT5
5.1 Introduction
Fatty acid synthase (FAS) is the key enzyme in de novo lipogenesis, catalyzing the
reactions for the synthesis of palmitate (Sul and Wang, 1998). FAS is regulated primarily at the
level of transcription and is sensitive to nutritional and hormonal regulation (Sul and Wang,
1998). Previous studies have demonstrated that growth hormone (GH), a cytokine which
activates signal transducer and activator of transcription 5 (STAT5) in adipocytes (Balhoff and
Stephens, 1998), abrogates the induction of FAS expression by insulin and down-regulates basal
expression of FAS in 3T3-F442A cells (Yin et al., 2001a). Although insulin-regulated regions of
the FAS promoter have been extensively studied, there has not been a conclusive study to
characterize a GH-responsive region or to determine the potential role of STATs in the
modulation of FAS expression. Since GH and prolactin (PRL) are potent activators of STAT5
(Balhoff and Stephens, 1998; Nanbu-Wakao et al., 2000), we hypothesized that STAT5 directly
regulates the expression of FAS. In this study we have demonstrated that GH and PRL treatment
of 3T3-L1 adipocytes resulted in a decrease of FAS mRNA and protein. In addition, we have
identified a region within the FAS promoter that is responsive to PRL. This region contains a
non-consensus STAT5 binding site, which, when mutated, results in a loss of sensitivity to PRL.
Our results clearly demonstrate that STAT5A binds to this non-consensus sequence and strongly
suggest that FAS is a direct target for regulation by STAT5. These data suggest a novel means
for regulation of FAS expression in adipocytes and reveal a mechanism by which STAT5
proteins and PRL exert anti-adipogenic effects.
5.2 Results
GH is known to reduce adipose tissue in vivo (Magri et al., 1990) and decrease the
expression of FAS in adipocytes (Yin et al., 1998). GH is also a potent activator of STAT5 in
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adipocytes (Balhoff and Stephens, 1998). Hence we hypothesized that STAT5 proteins directly
modulate FAS expression. Therefore, we examined the regulation of FAS by two STAT5
activators, GH and PRL. As shown in Fig. 5.1A, we observed that both GH and PRL resulted in
a decrease in FAS mRNA in fully differentiated 3T3-L1 adipocytes. GH decreased FAS mRNA
by 12 hours of treatment, and PRL treatment resulted in decreased expression within 6 hours. In
an independent experiment we observed that both GH and PRL also resulted in a decrease in
expression of FAS protein levels (Fig. 5.1B). To demonstrate the specificity of this effect, fully
differentiated 3T3-L1 adipocytes were treated with PRL for 8 hours with the various doses
indicated in Fig. 5.1C. There was a notable decrease in FAS protein level with 8.8 nM PRL
treatment, and the decrease of FAS protein levels by PRL treatment was dose-dependent. An
acute treatment of 1.3 µM PRL was included as a positive control for STAT5 phosphorylation.
The level of STAT5A expression was unchanged by GH or PRL (Fig. 5.1B and 5.1C) and is
shown to indicate even loading of protein samples.
Clearly, the analysis of mRNA and whole cell extracts demonstrated that activators of
STAT5 decreased expression of FAS protein and mRNA. Yet, it was unclear if the effects of
GH and PRL were mediated by affecting FAS transcription and/or protein turnover. To assess
whether the effects of PRL on FAS expression could be attributed to changes in the turnover of
FAS protein, we examined the loss of FAS in the presence of cycloheximide (5 µM) or ethanol, a
vehicle control. Whole cell extracts were collected at various times and used for Western blot
analysis. As shown in Fig. 5.2, either cycloheximide or prolactin treatment caused a decrease in
FAS protein. In the presence of cycloheximide, a loss of FAS was observed at 8 hours,
regardless of the presence of PRL. PRL treatment alone decreased the level of FAS within 12
hours of treatment. These results indicate that PRL does not affect the turnover of FAS protein
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Figure 5.1 Activators of STAT5 decrease expression of FAS in 3T3-L1 adipocytes. (A)
Total RNA was isolated from 3T3-L1 adipocytes following treatment with GH (11.3 nM) or
PRL (1.4 µM) for the times indicated in hours. Untreated cells (CTL) were harvested at the start
and end of the time course. Fifteen µg of total RNA was electrophoresed, transferred to nylon,
and subjected to Northern blot analysis with radiolabeled probe for FAS. Ethidium bromide
staining of 28S and 18S RNA is included as a loading control. This is a representative
experiment independently performed two times. (B) Mature 3T3-L1 adipocytes were stimulated
with GH (11.3 nM) or PRL (1.4 µM) for the times indicated. One hundred µg of protein from
whole cell extracts were loaded into the gel for each sample. The samples were subjected to
SDS-PAGE, and then were transferred to nitrocellulose for immunoblot analysis. This is a
representative experiment independently performed two times. (C) Mature 3T3-L1 adipocytes
were stimulated with PRL with the doses indicated for 8 hr. Western analysis was performed as
described above. This is a representative experiment independently performed two times.
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in 3T3-L1 adipocytes and suggest that PRL may exert its effects on FAS at the levels of
transcription.
PRL PRL/CHX
CTL
CHX
0 4 8 12 0 4 8 12 0 4 8 12 0 4 8 12 (hours)
260 kD

FAS

92 kD

STAT5A

Figure 5.2 PRL does not affect turnover of FAS protein. Fully differentiated 3T3-L1
adipocytes were treated with cycloheximide (CHX, 5 µM) and PRL (1.4 µM) for the times
indicated. One hundred µg of protein from whole cell extracts were loaded into the gel for each
sample. The samples were subjected to SDS-PAGE, and then were transferred to nitrocellulose
for immunoblot analysis. This is a representative experiment independently performed two
times.

Our data indicate that PRL may directly, transcriptionally regulate the expression of FAS.
Recent studies by Yin and colleagues (2001a) have shown that GH abrogates the induction of
FAS by insulin and suggested that the -112 to +65 region of the rat FAS promoter was sensitive
to the regulation by GH. Therefore, we hypothesized that a STAT5 recognition element may be
present in this region. Although the regulation of FAS by GH has been investigated, the
mechanism of regulation by PRL in adipocytes has not been elucidated. To address these
questions, 3T3-L1 preadipocytes were transiently transfected with a luciferase construct
containing the FAS promoter fragment of -250 to +65. After 48 hours, cells were stimulated
with PRL for the times indicated in Fig. 5.3A and then were analyzed for luciferase activity. We
observed that PRL treatment had no significant effects on the relative luciferase activity (Fig.
5.3A), clearly demonstrating that the -250 to +65 region of the FAS promoter is not sensitive to
PRL. Therefore, we examined the PRL responsiveness of two additional rat FAS
promoter/luciferase constructs that incorporated larger regions, -1594 to +65 and -700 to +65, of
the promoter. Transfection of these constructs into 3T3-L1 cells revealed a PRL-responsive
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region present between -1594 and -700 of the rat FAS promoter. As shown in Fig. 5.3B,
treatment with PRL resulted in a 64% decrease in luciferase activity of the rat FAS promoter
(-1594 to +65)/luciferase construct. Although the basal level of luciferase activity for the rat
FAS promoter (-700 to +65)/luciferase construct was similar to that of the -1594 to +65
construct, PRL had no effect on the level of luciferase activity (Fig. 5.3B). These data
demonstrate that a PRL-sensitive region exists between -1594 and -700 of the FAS promoter.
Since PRL is a potent activator of STAT5, we hypothesized that the -1594 to -700 region
of the FAS promoter may contain a STAT5 binding site conferring PRL responsiveness.
Therefore, we examined the rat FAS promoter (GenBank X62889) for the presence of STAT
consensus sites (TTCNNNGAA). An examination of the FAS promoter did not result in the
identification of any sequences that precisely matched the STAT consensus site. However, as
shown in Table 5.1, we identified four regions that were similar to the consensus sequence. To
evaluate these potential STAT5 binding sites, we performed a series of electrophoretic mobility
shift assays (EMSA). For these experiments, nuclear and cytosolic extracts were prepared from
3T3-L1 adipocytes that were acutely treated with PRL for 15 minutes. As shown in Fig. 5.4A,
PRL did not induce the binding of nuclear protein complexes to the -951 to -933, -1226 to -1214,
or -4639 to -4623 regions of the FAS promoter. The induction of binding by a PRL-activated
protein complex to the rat β-casein STAT5 binding site (Schmitt-Ney et al., 1991) is included as
a positive control. However, we did observe PRL-dependent binding by a nuclear protein
complex to the -908 to -893 region of the FAS promoter (Fig. 5.4B). In order to determine the
specificity of binding, an EMSA was performed using a mutant version of the -908 to -893
oligonucleotide, in which two nucleotides were changed (Table 5.1). As shown in Fig. 5.4B,
there was no detectable binding to the mutant form of the binding site following PRL
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Figure 5.3 A PRL responsive region resides between -1594 and -700 of the rat FAS
promoter. (A) Proliferating 3T3-L1 cells were transiently transfected with the rat FAS promoter
(-250 to +65)/luciferase construct and the TK/renilla vector to control for transfection efficiency.
After 48 hours of transfection, cells were stimulated with PRL (2.8 µM) for the times indicated.
Relative light units (RLU) were calculated by dividing firefly luciferase activity by renilla
luciferase activity. Results are shown as +/- standard deviation. (B) 3T3-L1 preadipocytes were
transiently transfected with the (-1594 to +65) or (-700 to +65) rat FAS promoter/luciferase
constructs. RLU was determined as described above.

stimulation. In addition, binding of the PRL-activated protein complex was successively
competed with increasing concentrations of the unlabeled -908 to -893 oligonucleotide (Fig.
5.4C). Further evidence of specificity is shown in Fig. 5.4D, in which an excess of the unlabeled
-908 to -893 oligonucleotide competed away binding induced by PRL treatment (Lane 4),
whereas the mutant form of the oligonucleotide did not (Lane 5). Although we did not detect

55

binding to the -951 to -933 site, an excess of this oligonucleotide moderately diminished binding
to the radiolabeled -908 to -893 probe (Lane 6). Yet, there was no appreciable competition of
binding by the -1226 to -1214 oligonucleotide (Lane 7). As anticipated, binding was competed
away with the STAT5 binding site of the rat β-casein promoter. Interestingly, a STAT3 binding
site, -168 to -148 from the rat α2-macroglobulin promoter (Hattori et al., 1990), which was
included as a control, also resulted in binding competition. However, binding was not competed
with a STAT 1 binding site that is present at -221 to -207 of the PPARγ2 promoter (Hogan and
Stephens, 2001).
Table 5.1 Potential STAT5 binding sites in the FAS promoter
Gene
Position
Sequence
Consensus GAS/SIE
TTC NNN GAA
FAS
-908 to -893
GGG TCC CGG AAA CCA G
FAS
mutant -908
GGG TCA AGG AAA CCA G
FAS
-951 to -931
C CCT TTC AAA AGA
FAS
-1226 to -1214 C TCC TTC CAC AGA GAG
FAS
-4639 to -4621 A ACT TTT TGA AAC
β-casein
-100 to -87
G GTT TTC TTG GAA TT

PRL Responsive

Yes
No
No
No
No
Yes

To determine if the protein complex binding the -908 to -893 contained STAT proteins,
we performed supershift analysis using antibodies directed against the STAT proteins expressed
in adipocytes. As shown in Fig. 5.5, the protein complex induced by PRL was fully supershifted
with a STAT5A antibody (lane 5) and weakly supershifted with a STAT5B antibody (lane 6).
STAT1 and STAT3 antibodies had no effect on the mobility of the complex (lanes 3 and 4). We
also investigated the specificity of binding by STAT proteins by comparing the binding induced
by LIF (0.5 nM), a cytokine which activates STAT1 and STAT3, but not STAT5 in 3T3-L1
adipocytes (Stephens et al., 1998). LIF stimulated binding to the -908 to -893 site by a protein
complex that exhibited highly reduced binding affinity and slightly faster mobility than the
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complex induced by PRL (Fig. 5.5). Moreover, the LIF-induced complex was supershifted by a
STAT1 antibody (lane 8), but not with antibodies for STAT3 or STAT5A (lanes 9 and 10).
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Figure 5.4 PRL stimulates binding of nuclear proteins to the -908 to -893 site in the rat FAS
promoter. (A) Nuclear extracts were prepared from differentiated 3T3-L1 adipocytes that were
untreated (-) or treated (+) with PRL (1.4 µM) for 15 min. For each sample, 10 µg of protein
were incubated with 50,000 cpm/ml of the indicated 32P-labeled probe of the FAS promoter. The
protein-DNA complexes were resolved by EMSA. Binding to the rat β-casein (-101 to -87) site
is included as a positive control. This is a representative experiment independently performed
two times. (B) Binding to the -908 to -893 and the mutant oligonucleotides by PRL-induced
protein complexes was analyzed as described above. (C) Successive cold competition was
performed with 75 nM to 15 µM of the unlabeled -908 to -893 oligonucleotide. EMSA was
performed as described above. (D) Nuclear extracts were preincubated with an excess of the
indicated unlabeled oligonucleotides (15 µM). EMSA was performed as described above.

Our data clearly demonstrate that the -908 to -893 region of the rat FAS promoter binds
nuclear PRL-activated STAT5 proteins in vitro. In order to determine if this region of the FAS
promoter contributed to the regulation of FAS by PRL in living cells, we performed site-specific
mutagenesis to alter two basepairs at positions -902 and -901 within the rat FAS promoter (-1594
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Figure 5.5 PRL induces STAT5A binding to the -908 to -893 site in the rat FAS promoter.
Nuclear extracts were prepared from 3T3-L1 adipocytes treated with PRL (1.4 µM) or LIF (0.5
nM) for 15 min. For each sample, 10 µg of protein were preincubated with 4 µg of the indicated
antibody and then incubated with 50,000 cpm/ml of the indicated 32P-labeled probe of the -908 to
-893 site in the FAS promoter. The protein-DNA complexes were resolved by EMSA. This is a
representative experiment independently performed two times.

to +65)/luciferase construct. We have shown that this mutation abolished binding of PRLinduced proteins to this site (Fig. 5.4B and 5.4D). Transfection of the wild-type and mutant
constructs into 3T3-L1 cells revealed that the basal level of luciferase activity was unaffected by
mutation of the -902 and -901 basepairs of the FAS promoter (Fig. 5.6). However, the 60%
decrease in luciferase activity induced by PRL for the wild-type construct was eliminated with
the mutation. Thus, these data clearly indicate that the -908 to -893 site of the FAS promoter is
sensitive to PRL and suggest that this site confers the negative regulation of FAS by PRLactivated STAT5A protein complexes.
5.3 Discussion

The novel data in this study include data demonstrating that FAS levels are decreased
following stimulation with activators of STAT5 in 3T3-L1 adipocytes, the identification of a
PRL-responsive region of the rat FAS promoter, and the characterization of a STAT5 binding
site in this region. These findings strongly suggest that STAT5A directly represses the
expression of FAS in adipocytes. Moreover, our data indicate that STAT5A has an anti-
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Figure 5.6 The -908 to -893 region of the rat FAS promoter confers sensitivity to PRL.
Proliferating 3T3-L1 cells were transiently transfected with the FAS (-1594 to +65)/luciferase
reporter wild-type construct or with the FAS m901/902 (-1594 to +65)/luciferase mutant
construct. Cells were also transfected with the TK/renilla construct to normalize for transfection
variability. After 48 hours of transfection, cells were stimulated with PRL (2.8 µM) for the times
indicated. Relative light units (RLU) were calculated by dividing firefly luciferase activity by
renilla luciferase activity. Results are shown as +/- standard deviation.

lipogenic function in mature adipocytes, in addition to an adipogenic role previously described
by our laboratory (Floyd and Stephens, 2003) and others (Yarwood et al., 1995; Teglund et al.,
1998; Shang et al., 2003), indicating that the functions of STAT5A may depend on the
developmental stage of the cells
Previous studies have shown that GH, an activator of STAT5, attenuated the induction of
FAS in adipocytes by insulin in 3T3-F442A adipocytes (Yin et al., 1998) and decreased
expression of FAS in vivo (Magri et al., 1990). We observed that two activators of STAT5 in
adipocytes, GH and PRL, decreased protein and mRNA expression of FAS in 3T3-L1
adipocytes. These results are consistent with the findings that GH (Lanna et al., 1995) and PRL
(Flint et al., 1981) inhibit the activity of FAS in adipose tissue. Our results indicate that PRL did
not affect the protein turnover of FAS, but indicated that changes in FAS levels are mediated at
the transcriptional level. Our experiments are supported by other studies which demonstrate that
FAS can be modulated at the transcriptional level (Bennett et al., 1995; Roder et al., 1997;
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Boizard et al., 1998; Kim et al., 1998; Sul and Wang, 1998; Yin et al., 2001a). However,
increased turnover of FAS mRNA in 3T3-F442A adipocytes has been demonstrated as one of the
means through which GH attenuates the induction of FAS by insulin (Yin et al., 1998).
Nonetheless, our results strongly suggest that the PRL-induced repression of FAS is mediated by
an inhibition of transcription.
In order to elucidate the mechanism of transcriptional regulation by PRL, we investigated
the regulation of the FAS promoter. Although a previous study indicated that the -112 to +65
region of the rat FAS promoter was sensitive to regulation by GH (Yin et al., 2001a), we did not
observe PRL-mediated regulation of the rat FAS promoter within this region (Fig. 5.3A).
However, our analysis of larger regions of the rat FAS promoter clearly indicated that a PRLresponsive region existed between -1594 to -700 of the rat FAS promoter (Fig. 5.3B). Yin and
co-workers (2001a) have previously shown that GH attenuated the stimulation by insulin of the
rat FAS promoter (-112 to +65)/luciferase construct, a region of the promoter which does not
contain a STAT consensus site. Furthermore, in another study, it was demonstrated that
staurosporine, an inhibitor of JAK/STAT signaling, did not block the effect of GH on insulinstimulated FAS expression (Yin et al., 2001b). Thus, it is unlikely that STAT5 proteins mediate
the inhibitory effects of GH on insulin regulation of FAS. Yet, in light of our current findings,
we postulate that the repression of basal levels of FAS by PRL is directly regulated by STAT5
proteins via binding to a site within the -1594 to -700 region of the rat FAS promoter.
Since PRL is a potent activator of STAT5 (Fig. 5.1B), we examined the rat FAS promoter
for sites that resembled the STAT consensus sequence, TTCNNNGAA. We identified four sites
that were similar to the STAT consensus, but our analysis by EMSA indicated that only one site,
at position -908 to -893, was bound by a PRL-induced nuclear protein complex. We have also
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shown that binding was specific (Fig. 5.4). In our experiments, the PRL-induced protein
complex was fully supershifted by a STAT5A antibody (Fig. 5.5). The functional significance of
the -908 to -893 site was determined by mutating two nucleotides at positions -902 and -901,
within the STAT5 binding site of the rat FAS promoter (-1594 to +65)/luciferase construct.
Mutation of this site completely abrogated the downregulation by PRL that was observed with
the wild-type construct (Fig. 5.6). Taken together, these data strongly suggest that -908 to -893
of the rat FAS promoter is a STAT5 binding site which confers the negative transcriptional
regulation of FAS by PRL. These results support our hypothesis that STAT5 directly represses
expression of FAS in adipocytes.
The association of increased transcription of FAS in rodent obesity (Guichard et al.,
1992) and the inhibition of adipogenesis by an allosteric inhibitor of FAS (Liu et al., 2004) are
highly indicative that regulation of FAS expression and activity in adipocytes is an important
control of energy homeostasis. The characterization of a STAT5 binding site in the rat FAS
promoter identifies a novel mechanism for repression of FAS expression. The -908 to -893 site
of the rat FAS promoter is also present in the murine FAS promoter (AL663090) at position -895
to -887. Interestingly, the human FAS promoter (AF250144) contains a site at -1091 to -1083
(TTCGAGGAA) which is different from the sequence identified from the rodent promoters, but
complements the STAT consensus sequence, TTCNNNGAA. Hence, although the precise
sequence of the STAT5 binding site is not conserved across species, the binding by STAT5 to
these sites in the FAS promoter may be an evolutionarily retained mechanism of regulating FAS
expression in adipose tissue.
Our observation that STAT5A, not other adipocyte STATs, preferentially binds to the
-908 to -893 site (Fig. 5.5) is consistent with previous studies demonstrating that STAT proteins
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bind similar sequences but exhibit subtle differences in affinity for nucleotides between and
beyond the half sites of the palindrome (Soldaini et al., 2000; Ehret et al., 2001). This specificity
in STAT binding may account for the distinct repertoire of target genes regulated by each STAT
protein (Ehret et al., 2001). Our data suggest that the regulation of transcription mediated by the
-908 to -893 region of the rat FAS promoter is primarily regulated by STAT 5A binding.
PRL has been shown to have anti-lipogenic effects in adipose tissue through inhibition of
LPL expression and the repression of FAS (Flint et al., 1981) and LPL activity (Ling et al.,
2003). Our results strongly suggest that PRL modulates the expression of FAS in adipocytes
through STAT5A and support a role for STAT5 as a regulator of energy balance in adipocytes.
PRL appears to have dual functions, positively and negatively affecting adipocyte gene
expression. The association of STAT5 proteins with coactivators, corepressors and other
transcription factors likely affect the ability of STAT 5A to have adipogenic and anti-adipogenic
effects. Recent work from our laboratory has demonstrated that the association between
STAT5A and the glucocorticoid receptor (GR) is highly regulated during fat cell differentiation
(Floyd et al., 2003). Hence, cooperation between STAT5A and GR may occur in the modulation
of FAS since glucocorticoids have been demonstrated to affect FAS transcription and activity in
adipose tissue (Volpe et al., 1975; Wang et al., 2004). In summary, we have observed that PRL
represses expression of FAS in adipocytes and negatively regulates the rat FAS promoter. Our
identification of a STAT5 binding site in the promoter of FAS characterizes a novel mechanism
of regulating FAS expression. We hypothesize that the regulation of FAS by STAT5 is likely an
important contribution to the maintenance of energy homeostasis.
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CHAPTER 6: THE EFFECTS OF LEUKEMIA INHIBITORY FACTOR ON
ADIPOCYTES
6.1 Introduction
Leukemia inhibitory factor (LIF) is a member of the gp130 cytokine family, cytokines
which are unrelated by sequence, but are structurally similar and share a common receptor,
gp130 (Robinson et al., 1994; Kishimoto et al., 1995). LIF has multiple effects on adipocytes
and adipose tissue, stimulating a wasting weight loss in mice engrafted with a tumor cell line that
overproduces LIF (Mori et al., 1989), inhibiting lipoprotein lipase (LPL) expression and activity
in 3T3-L1 and 3T3-F442A adipocytes (Marshall et al., 1994), promoting adipogenesis of ob1771
cells (Aubert et al., 1999), and preventing adipogenesis in bone marrow stromal cells (Gimble et
al., 1994). These findings suggest that the diverse effects of LIF on adipocytes depend on the
developmental stage of the cells or tissue.
Recent work in our laboratory has examined the effects of two other gp130 cytokines,
ciliary neurotropic factor (CNTF) and cardiotrophin-1 (CT-1), on adipocytes (Zvonic et al.,
2003; Zvonic et al., 2004). CNTF increased expression and activation of insulin signaling
proteins in 3T3-L1 adipocytes, but decreased expression of fatty acid synthase (FAS) and sterol
regulatory element binding protein-1 (SREBP1). Like CNTF, CT-1 decreased expression of
FAS protein but also decreased expression of insulin receptor substrate-1 (IRS-1) in 3T3-L1
adipocytes, indicating both overlapping and divergent effects of gp130 cytokines on adipocytes.
To further elucidate the role of gp130 cytokines on adipocytes, we have investigated the action
of LIF on 3T3-L1 adipocytes. As previously observed with CT-1 and CNTF, LIF neither
promoted nor attenuated adipogenesis, in contrast to previous findings for LIF (Gimble et al.,
1994; Aubert et al., 1999). We have also shown that FAS and SREBP1 protein levels decreased
after a chronic treatment with LIF. In addition, both suppressor of cytokine signaling-3 (SOCS3)
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and CCAAT/enhancer binding protein-δ (C/EBPδ) mRNA were rapidly induced following
treatment of adipocytes with LIF. We identified three signal transducer and activator of
transcription-1 (STAT1) binding sites in the C/EBPδ promoter at positions -696 to -679, -810 to
-793, and -1491 to -1475. Unlike other gp130 cytokines, LIF had no effect on basal or insulinstimulated glucose uptake, or on the expression of glucose transporter 4 (GLUT4). In summary,
our results demonstrate novel and specific effects of LIF on adipocytes, suggesting a role for LIF
as a regulator of lipid synthesis and an effector of signal transduction in adipocytes.
6.2 Results
To determine if LIF treatment could modulate adipogenesis, 3T3-L1 preadipocytes were
induced to differentiate in the presence or absence of exogenous LIF. The cells were exposed to
LIF (0.5 nM) for the entire course of differentiation with a fresh bolus of LIF added at the time
of induction and every 24 hours after that. Whole cell extracts were harvested at the time points
indicated in Fig. 6.1 and were analyzed by Western blotting. Adipogenesis was assessed by
induction of peroxisome proliferator-activated receptor-γ (PPARγ), FAS, and STAT5A proteins
(Spiegelman et al., 1993; Chawla et al., 1994; Stephens et al., 1996). Although LIF attenuated
the induction of FAS at 48 hours and 72 hours, LIF did not affect the overall expression of these
markers of adipogenesis. The expression of STAT3 does not change during adipogenesis
(Stewart et al., 1999) and is shown as a loading control (Fig. 6.1). Phosphorylation of STAT3
was detected in preadipocytes following 15 minutes of stimulation with LIF. A longer exposure
of the film detected a low level of STAT3 phosphorylation through the course of differentiation.
Since LIF is a potent activator of STATs 1 and 3 in 3T3-L1 cells (Stephens et al., 1998)
we examined the action of LIF on mature adipocytes. Whole cells extracts were collected from
fully differentiated 3T3-L1 adipocytes that were treated with LIF for the various times indicated
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Figure 6.1 LIF does not affect the differentiation of 3T3-L1 adipocytes. Whole cell extracts
were prepared from 3T3-L1 preadipocytes (PA) or 3T3-L1 cells induced to differentiate in the
presence or absence of LIF (0.5 nM). Cells were treated every 24 h with a fresh bolus of LIF.
Seventy-five µg of each sample were separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. The detection system was horseradish peroxidase-conjugated
secondary antibodies and enhanced chemiluminescence. This is a representative experiment
independently performed three times.
in Fig. 6.2. Although the phosphorylation of STATs 1 and 3 was detected at 15 and 45 minutes
of stimulation, there were no changes in the level of PPARγ, the insulin-regulated transcription
factor Foxo1, SREBP1, FAS, or acetyl coA carboxylase (ACC) proteins during the time course
(Fig. 6.2). Therefore, we investigated the effect of a chronic LIF treatment on 3T3-L1
adipocytes. Fully differentiated adipocytes were stimulated with LIF for the times indicated in
Fig. 6.3, with a fresh bolus of LIF added every 24 hours. Chronic LIF treatment resulted in
decreased protein levels of FAS and SREBP1 at 120 hours, but the levels for Foxo1, PPARγ,
LPL, and ACC were unchanged. Efficacy of LIF treatment is shown by the phosphorylation of
STAT3 during the time course, and positive controls for activation of STATs 1, 3, and 5 are
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shown with extracts from 3T3-L1 adipocytes stimulated for 15 minutes with IFNγ, LIF, and
growth hormone (GH), respectively.

LIF
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91/84 kD
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STAT 3 Tyr705
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PPARγ
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Foxo1
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260 kD

FAS

265 kD
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Figure 6.2 Acute LIF treatment did not affect expression of adipocyte marker proteins.
Mature 3T3-L1 adipocytes were treated with LIF (0.5 nM) for the times indicated. Seventy-five
µg of protein from whole cell extracts were loaded into the gel for each sample. The samples
were subjected to SDS-PAGE, and then were transferred to nitrocellulose for immunoblot
analysis. This is a representative experiment independently performed two times.

Since other gp130 cytokines have been reported to have effects on insulin signaling and
glucose uptake, we investigated the ability of LIF to regulate glucose uptake in 3T3-L1
adipocytes. Mature 3T3-L1 adipocytes were pretreated with LIF for 30 minutes, 48 hours or 96
hours. Adipocytes were stimulated with insulin for 15 minutes and assayed for uptake of [3H] 2deoxyglucose. As shown in Fig. 6.4, insulin treatment induced an approximately 4-fold increase
in glucose uptake, regardless of the acute or chronic treatments of LIF (ANOVA F (7,16) =
123.37, p = 1.02E-12; Scheffé’s test). We observed no significant differences for basal glucose
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uptake by adipocytes. Furthermore, there were no effects on the level of GLUT4 mRNA over a
time course of 24 hours (Fig. 6.5).
LIF
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STAT 3
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91 kD

STAT 1 Tyr701

91 kD

STAT 3 Tyr705 (lighter exposure)

91 kD

STAT 3 Tyr705 (darker exposure)

92 kD

STAT 5 Tyr694
(+)

Figure 6.3 The effects of chronic treatment of LIF on 3T3-L1 adipocytes. Whole cell
extracts were prepared from fully differentiated 3T3-L1 adipocytes following treatment with LIF
(0.5 nM) for the indicated times. Cells were treated every 24 h with a fresh bolus of LIF.
Seventy-five µg of each sample were separated by SDS-PAGE, transferred to nitrocellulose, and
subjected to Western blot analysis. (+) indicates a positive control of a 15-min treatment with
IFNγ, LIF, and GH for activation of STAT1, STAT3, and STAT5, respectively. This is a
representative experiment independently performed two times.

To examine the effects of LIF on the regulation of mRNA for several adipocyte genes
which could not be analyzed by Western blot because effective antibodies are not available for
the proteins, total RNA was collected from fully differentiated 3T3-L1 adipocytes following
treatment with LIF for the times indicated in Fig. 6.5. Although no changes were detected for
expression of C/EBPα, C/EBPβ, or the fatty acid binding protein, aP2, LIF induced a rapid and
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transient upregulation of mRNA for SOCS3 and C/EBPδ within one hour of stimulation.
Furthermore, the upregulation of SOCS3 and C/EBPδ was independent of extracellular signal
regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) activity, as pretreatment with
the MAPK kinase (MEK) inhibitor, U0126, did not block the induction by LIF (data not shown).
Induction of SOCS3 by gp130 cytokines has been demonstrated in adipocytes (Zvonic et al.,
2004) and is well characterized in other cell types (Krebs and Hilton, 2001).
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Figure 6.4 LIF does not affect insulin stimulation of glucose uptake. Fully differentiated
3T3-L1 adipocytes were treated with LIF (0.5 nM) for the times indicated. Cells were treated
every 24 h with a fresh bolus of LIF. Cells were serum deprived 4 h and then stimulated with
insulin (44 nM) for 15 min. Glucose uptake was initiated by addition of [3H] 2-deoxyglucose.
Glucose uptake for each time point was measured in triplicate and is given as the mean +/- the
standard deviation. Asterisks indicate statistically significant differences compared to untreated
samples (*, p < 0.01; Scheffé’s test; ANOVA F (7,16) = 123.37, p = 1.02E-12). This is a
representative experiment independently performed two times.

The role of STAT3 in the upregulation of C/EBPδ has been investigated in other cell
types, and evidence indicated that the -115 to -98 site in the C/EBPδ promoter was bound by
STAT3 following stimulation with interleukin-6 (IL-6) (Yamada et al., 1997; Hutt et al., 2000).
Hence, we examined the ability of LIF to induce binding to the -115 to -98 element of the
C/EBPδ promoter. Electrophoretic mobility shift assay (EMSA) was performed with nuclear
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extracts from 3T3-L1 adipocytes treated with LIF for 15 minutes. As shown in Fig. 6.6, no
detectable binding to the -115 to -98 oligonucleotide was observed with LIF treatment, indicating
that this site does not contribute to the regulation of C/EBPδ by LIF in 3T3-L1 adipocytes.
Thus, we looked for other possible STAT binding sites in the C/EBPδ promoter and identified
four sites at positions -616 to -599, -696 to -679, -780 to -763, and -1491 to -1475 which
resembled the consensus STAT recognition sequence TTCNNNGAA (Table 6.1). As shown in
Fig. 6.6, LIF-induced nuclear protein complexes shifted the sites at -696 to -679, -780 to -763,
and -1491 to -1475, but not the -616 to -599 oligonucleotide (data not shown). In addition, we
observed faint bands of cytoplasmic proteins from LIF-treated adipocytes for the -780 to -763
and the -1491 to -1475 oligonucleotides, which may be indicative that the protein complex that
binds to these sites forms in the cytoplasm.
CTL
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Figure 6.5 LIF induces the expression of C/EBPδ and SOCS3 mRNA. Total RNA was
isolated from 3T3-L1 adipocytes following treatment with LIF (0.5 nM) for the times indicated
above. Untreated cells (CTL) were harvested at the start and end of the time course. Fifteen µg
of total RNA was electrophoresed, transferred to nylon, and subjected to Northern blot analysis
with radiolabeled probes for the indicated genes. Hybridization to β-actin is included as a
loading control. This is a representative experiment independently performed two times.
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Figure 6.6 LIF activates binding by protein complexes from the nuclei of 3T3-L1
adipcoytes to three sites of the C/EBPδ promoter. Nuclear extracts were prepared from
differentiated 3T3-L1 adipocytes that were untreated or treated with LIF for 15 min. For each
sample, 10 µg of protein were incubated with 50,000 cpm/ml of the indicated 32P-labeled probe
of the C/EBPδ promoter. The protein-DNA complexes were resolved by electromobility shift
assay. This is a representative experiment independently performed two times.
Table 6.1 STAT binding sites in the C/EBPδ promoter
Gene
Position
Sequence
Consensus GAS/SIE
TTC NNN GAA
C/EBPδ
-115 to -98
TCG TTC CCA GCA GCA AC
C/EBPδ -616 to -599 AGC TTT AAT AAC CAA G
C/EBPδ -696 to -679 AAT TTC AGA ATA ATA TCC
C/EBPδ -780 to -763 CTT TTC ACG AAT TTT GAA
C/EBPδ -1491 to -1475 CGT TTC CCG TAA ATC CCT CCC
α2-M
-168 to -148 TCC TTC TGG GAA TC
m67
CGT TTC CCG TAA ATC CCT CCC

LIF Responsive

No
No
Yes
Yes
Yes
Yes
Yes

Since LIF is a strong activator of STAT3 (Figs. 6.2 and 6.3), we hypothesized that the
protein complex contained STAT3. However, supershift analysis using multiple STAT3
antibodies, along with antibodies against STAT1 and STAT5A clearly indicates that the protein
complex induced by LIF primarily contains STAT1 (Fig. 6.7, panels 1-3, lane 7). As shown in
Fig. 6.7, supershift was not detected with a STAT5A antibody (lane 8) or with STAT3 antibodies
which recognize the carboxy terminus (lane 4), amino acids 1-175 (lane 5), or amino acids 688722 (lane 6) of STAT3. We also examined the induction of binding by LIF-induced proteins to
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two oligonucleotides that are routinely used as positive controls for STAT3 binding, the -168 to
-148 site from the rat α2-macroglobulin (α2M) promoter (Hattori et al., 1990) and the m67
oligonucleotide derived from the c-fos -345 to -323 promoter (Wagner et al., 1990). As shown
in Fig. 6.7A, LIF treatment induced binding to these oligonucleotides (panels 4 and 5, lane 3).
Similar to our findings with the C/EBPδ promoter sites, only STAT1 antibody supershifted the
protein complex induced by LIF for both the m67 and α2M oligonucleotides. To further
investigate the activation of STAT3 binding by LIF, we used a longer m67 oligonucleotide for
EMSA analysis (Fig. 6.7B). We detected binding by two protein complexes that were induced
by LIF. The weak binding by the protein complex exhibiting slower mobility was blocked by
antibodies for STAT3 (lanes 4 and 5). The more prominent protein complex exhibiting faster
mobility was supershifted by STAT1 antibody (lane 6). STAT5A antibody was included as a
negative control. Thus, although LIF is a potent activator of STAT3, STAT1 appears to
preferentially bind under these conditions in 3T3-L1 adipocytes. Furthermore, our supershift
analysis suggests that STAT1 contributes to the LIF-induced modulation of C/EBPδ in
adipocytes.
6.3 Discussion

Recent work from our laboratory has demonstrated that gp130 cytokines, CT-1 and
CNTF, have overlapping and divergent effects on the expression and activation of proteins of
lipid and glucose metabolism in adipocytes (Zvonic et al., 2003; Zvonic et al., 2004). The gp130
cytokines activate the JAK/STAT pathway via the gp130 and LIFR receptors. Because LIF also
signals through gp130 and LIFR, we hypothesized that LIF would regulate adipocyte proteins.
Our studies with 3T3-L1 cells have shown that LIF activates STATs 1 and 3 in preadipocytes
and mature adipocytes. Because LIFR is expressed more abundantly in preadipocytes (Zvonic et
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Figure 6.7 Binding of LIF-activated STAT1, not STAT3, to sites in the C/EBPδ promoter.
(A) Nuclear extracts were prepared from differentiated 3T3-L1 adipocytes that were untreated or
treated with LIF for 15 min. For each sample, 10 µg of protein were incubated with 50,000
cpm/ml of the 32P-labeled probe (indicated above) of the C/EBPδ promoter or of the STAT3
oligonucleotides for m67 or -168 to -148 site of the rat α2M promoter. For supershift, samples
were preincubated with the indicated antibodies (4 µg): STAT3 1 (Santa Cruz C-20), 2
(Transduction Laboratories), 3 (Upstate); STAT1 (Upstate); and STAT5 (Santa Cruz L-20). The
protein-DNA complexes were resolved by electromobility shift assay. This is a representative
experiment independently performed two times. (B) Nuclear extracts from untreated or LIFtreated 3T3-L1 adipocytes were incubated with the 32P-labeled 33-base pair m67 oligonucleotide.
For supershift analysis, samples were preincubated with the indicated antibodies.
al., 2003), we predicted that LIF would regulate adipogenesis. However, there were no effects of

LIF on the in vitro differentiation of 3T3-L1 adipocytes. In another cell line, Ob1771, LIF
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promoted differentiation (Aubert et al., 1999). Thus, it is possible that this discrepancy is due to
differences in commitment to the adipocyte lineage of these two cell lines.
Since adipocytes are responsive to LIF, we studied the effects of this cytokine on fully
differentiated adipocytes. Acute treatment did not regulate the expression of several adipocyte
proteins, but expression of SOCS3 and C/EBPδ mRNA was strongly and transiently stimulated
by LIF. SOCS3 is a member of the SOCS protein family which is characterized by their ability
to negatively modulate cytokine signaling (Krebs and Hilton, 2001). The induction of SOCS3
expression has been demonstrated by many cytokines, and direct regulation by STAT proteins
has been described (Auernhammer et al., 1999). These data are consistent with recent findings
from our laboratory that CNTF and CT-1 upregulate SOCS3 mRNA (Zvonic et al., 2004).
Interestingly, there is recent evidence that SOCS3 is a regulator of insulin signaling and may
cause insulin resistance in adipocytes through its effects on insulin receptor subunit (IRS) protein
expression (Shi et al., 2004). Although we did not observe effects on insulin-stimulated glucose
uptake by LIF, the upregulation of SOCS3 by gp130 cytokines is clearly a major component of
JAK/STAT signaling in adipocytes.
C/EBPδ is a basic-leucine zipper transcription factor with a well-established role in
adipogenesis (Darlington et al., 1998), although knock-out studies indicate that C/EBPδ alone is
weakly adipogenic (Tanaka et al., 1997). The IL-6-induced upregulation of C/EBPδ in
mammary epithelium (Hutt et al., 2000) and HepG2 cells (Yamada et al., 1997) has been shown
to be mediated by the -115 to -98 region of the promoter, but our data indicated that this site was
not sensitive to LIF regulation in adipocytes (Fig. 6.6). However, three other sites at positions
-696 to -679, -780 to -763, and -1491 to -1475 were bound by LIF-activated protein complexes
which contained STAT1 (Fig. 6.6). Interestingly, the protein complex did not contain STAT3, as
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we had predicted, as LIF is a more potent activator of STAT3 than STAT1, as shown in Fig. 6.2.
Moreover, we did not observe STAT3 binding to two oligonucleotides routinely used as positive
controls for STAT3 binding, -168 to -148 site of the rat α2M promoter (Hattori et al., 1990) and
m67 (Wagner et al., 1990). Yet, our supershift analysis revealed that these oligonucleotides
were shifted by protein complexes which contained STAT1. Only when we used a long form of
the m67 oligonucleotide did we detect a faint band that represented STAT3 binding. Our
observations strongly suggest that STAT1 preferentially binds under these conditions in 3T3-L1
adipocytes. These results have led us to hypothesize that the three sites in the C/EBPδ promoter
confer the LIF response and that binding by STAT1 may mediate the upregulation of C/EBPδ in
adipocytes.
The consequences of increased expression of C/EBPδ in mature adipocytes are not
known. It has been shown that tumor necrosis factor-α (TNFα) (Kurebayashi et al., 2001),
dexamethasone (MacDougald et al., 1994), and insulin (MacDougald et al., 1995) also
upregulate C/EBPδ in mature adipocytes in a rapid and transient manner. Interestingly, the lack
of effect of LIF on C/EBPα expression suggests that although C/EBPα is regulated by C/EBPδ
in differentiating adipocytes (Lane et al., 1999), it is not affected by C/EBPδ expression in
mature adipocytes. In other cell types, C/EBPδ negatively regulates the expression of the α2
chain of type I collagen, a critical structural component of the extracellular matrix (Greenwel et
al., 2000). C/EBPδ upregulates expression of IL-6 in astrocytes (Schwaninger et al., 2000),

intestinal epithelial cells (Hungness et al., 2002), and osteoblasts (Ruddy et al., 2004); thus, IL-6,
an adipokine associated with obesity (Bastard et al., 2000), may be a transcriptional target of
C/EBPδ in adipocytes as well. Effects on C/EBPδ targets would likely be transient, since the
induction of C/EBPδ is short-lived (MacDougald et al., 1994). These potential outcomes of
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increased C/EBPδ expression give insight into one means by which LIF exerts effects on
adipocyte function.
We also examined the effect of a chronic administration of LIF in fully differentiated
adipocytes. Both FAS and SREBP1 proteins exhibited decreased expression after 120 hours of
LIF stimulation. FAS is the enzyme catalyzing all of the steps in the synthesis of palmitate from
acetyl CoA and malonyl, and the level of its expression is coupled to the rate of lipogenesis (Sul
and Wang, 1998). SREBP1 is a transcription factor known to modulate genes associated with fat
and cholesterol metabolism (Horton et al., 2002), including FAS (Bennett et al., 1996). The
decreased expression of SREBP1 and FAS may result in changes in lipid accumulation in
adipocytes as a result of prolonged exposure to LIF in vivo. Since the effect of LIF on the
expression of SREBP1 and FAS was not evident until 120 hours, it is unlikely that the downregulation was mediated by STAT proteins.
In light of recent studies demonstrating upregulation of GLUT4 expression by CNTF
(Zvonic et al., 2003) and improved insulin-stimulated glucose uptake by CT-1 (Zvonic et al.,
2004), we investigated the ability of LIF to modulate glucose uptake in adipocytes. Our findings
clearly demonstrate that LIF does not affect basal or insulin-stimulated glucose uptake, and does
not modulate expression of GLUT4. Thus, LIF likely does not affect glucose disposal in adipose
tissue.
In summary, we have demonstrated that LIF activates the JAK/STAT pathway in 3T3-L1
preadipocytes and adipocytes. Although LIF had no effect on adipogenesis of 3T3-L1 cells, LIF
increased C/EBPδ expression after an acute exposure. We have identified three LIF-responsive
sites in the C/EBPδ promoter that are distinct from the previously reported STAT3 binding site
for IL-6 regulation in mammary epithelial cells (Hutt et al., 2000) and hepatocytes (Yamada et
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al., 1997). Moreover, these three newly identified and LIF-responsive sites bind STAT1, rather

than STAT3. LIF, similar to CT-1 and CNTF, regulated proteins involved in lipid accumulation,
SREBP1 and FAS, which may be indicative of a redundant role of gp130 cytokines in the
modulation of adipocyte function. However, unlike these cytokines, LIF had no effect on basal
or insulin-stimulated glucose uptake. These results were somewhat unexpected, given that all
three cytokines signal through the same receptor components. Yet each cytokine activates a
unique pattern of STATs in adipocytes. CNTF only activates STAT3 (Zvonic et al., 2003),
whereas LIF activates STATs 1 and 3, and CT-1 activates STATs 1, 3, and 5 (Zvonic et al.,
2004). Therefore, we predict that the variation in recruitment of these transcription factors
mediates the nonredundant, downstream effects of gp130 cytokines in 3T3-L1 adipocytes.
Furthermore, crosstalk with other signaling pathways may contribute to the divergent effects of
gp130 cytokines. Current studies are underway to investigate the crosstalk among gp130
cytokines in adipocytes.
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CHAPTER 7: SUMMARY AND CONCLUSIONS
Recent advances in our understanding of adipocyte biology have brought closer the
possibilities of treating obesity, but have also emphasized the need for further research to better
understand the complexities of mature adipocytes. Adipose tissue is highly dynamic, responding
to and directing changes in energy metabolism. These responses culminate from changes in gene
expression regulated by transcription factors. Thus, the activation and action of transcription
factors in adipocytes is an important focus of research. The results presented in this dissertation
describe STAT binding sites in the promoters of four adipocyte genes.
Five members of the STAT transcription factor family are known to be expressed in
adipocytes; STATs 1, 5A, and 5B are highly induced during adipogenesis, and STATs 3 and 6
are expressed in preadipocytes and adipocytes (Stephens et al., 1996; Stewart et al., 1999). The
expression of these proteins is strongly indicative of a role for STATs in modulating genes in
adipocytes. STAT5A has been demonstrated to induce adipogenesis (Floyd and Stephens,
2003). Yet, specific STAT 5 targets have not been identified. Moreover, the function of STATs
in mature adipocytes is not known. Our characterization of STAT binding sites in the promoters
of PPARγ2, LPL, FAS and C/EBPδ strongly suggest that these adipocyte genes are regulated by
STATs in vivo.
The negative regulation of PPARγ, LPL and FAS by cytokines implicates STATs as
repressors of transcription. Although STATs are best known as activators of transcription,
negatively regulated gene targets have been identified in other tissues (Sharma et al., 1998; Ikeda
et al., 1999; Ramana et al., 2000). It is speculated that STATs repress transcription by
interacting with corepressors, such as Blimp-1, myc-binding protein-1 (MBP-1), silencing
mediator for retinoid and thyroid hormone receptors (SMRT), protein inhibitor of activated
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STAT-y (PIASy) (Ramana et al., 2000; Dong and Tweardy, 2002; Liu et al., 2001) or that
naturally occurring truncations lacking the transcriptional activation domain bind promoter
elements to inhibit transcription (Kisseleva et al., 2002). We hypothesize that in adipocytes,
negative regulation by STATs occurs through the recruitment of corepressors since we have not
detected the expression of truncated STAT isoforms. The identification of proteins which bind
STATs in the nucleus would further elucidate the mechanism of STAT-regulated transcription.
We have demonstrated that PPARγ is a negatively regulated target of STAT1 in 3T3-L1
adipocytes through the identification of a STAT1 binding site at the -221 to -207 position of the
PPARγ2 promoter. This site was bound by nuclear STAT1 activated by IFNγ, CT-1, and LIF.
However, binding to this site correlated with transcriptional repression by IFNγ and CT-1 but not
LIF, which had no detectable effects on PPARγ expression. Our studies have shown that the
PPARγ2 promoter contains a STAT1 binding site that likely mediates transcriptional repression
of PPARγ by CT-1 and IFNγ. Although LIF-activated STAT1 bound to the site in the PPARγ2
promoter, LIF is a much less potent activator of STAT1 than IFNγ (Hogan and Stephens, 2001).
Hence, an insufficient level of STAT1 may be present in the nucleus following stimulation with
LIF in order to regulate PPARγ expression. Since decreased cellular levels of PPARγ confer
resistance to weight gain (Miles et al., 2000; Kubota et al., 1999), we speculate that STAT1
serves to prevent expansion of adipose tissue, in part through the downregulation of the
adipogenic transcription factor, PPARγ.
Multiple studies have demonstrated a decrease in LPL mRNA expression and activity
following stimulation of adipocytes with IFNγ. We have demonstrated a decrease in LPL protein
following IFNγ treatment of 3T3-L1 adipocytes. Furthermore, we have identified a STAT1
binding site in the LPL promoter at position -938 to -921. LPL is the rate-limiting enzyme
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catalyzing the hydrolysis of serum triglycerides for uptake by underlying tissues. Therefore, the
downregulation of LPL by STAT1 would ostensibly decrease uptake of fatty acids for storage in
adipose tissue. Furthermore, we propose that STAT1 mediates the lipolytic effects of IFNγ in fat
cells and may function to limit storage of lipid in adipose tissue.
We have demonstrated that FAS expression decreases following treatment of 3T3-L1
adipocytes with GH and PRL, potent activators of STAT5 proteins. Our studies with serial
deletions of the FAS promoter reporter constructs indicated the presence of a PRL responsive
region between -1594 and -700 basepairs of the FAS promoter. We identified a STAT5 binding
site at position -908 to -893, which was bound by a protein complex containing STAT5A.
Moreover, the functional significance of this site was determined by the site-directed mutation of
two basepairs within the -908 to -893 site in a FAS promoter reporter construct. FAS is the
central enzyme of de novo lipogenesis, and although the majority of lipid stored in adipose tissue
comes from diet, de novo lipogenesis contributes to the accumulation of stored lipid (Wang et
al., 2004). Previous studies have clearly identified STAT5A as an adipogenic transcription
factor, but our results indicate that STAT5A may also be anti-lipogenic in mature adipocytes.
Finally, we examined the effects of LIF, a gp130 cytokine, on 3T3-L1 adipocytes. LIF
robustly activates STAT3, but also activates STAT1. We did not observe significant effects of
LIF on adipogenesis of 3T3-L1 adipocytes. Furthermore, LIF did not acutely affect the
expression of several adipocyte marker proteins and did not modulate basal or insulin-stimulated
glucose uptake. However, following a chronic stimulation with LIF, the expression of SREBP1
and FAS were notably decreased. In addition, we observed the rapid and transient upregulation
of SOCS3 and C/EBPδ mRNA. Although a previously described STAT3 site in the C/EBPδ
promoter did not bind LIF-activated protein complexes, three new sites in the promoter at
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positions -696 to -679, -810 to -793, and -1491 to -1475 were bound by LIF-activated STAT1
from 3T3-L1 adipocytes. Thus, we propose that these sites confer the positive regulation of
C/EBPδ by LIF. It is unclear what the consequence is of transient C/EBPδ upregulation in
adipocytes, but it has been shown to also occur following stimulation of adipocytes with TNFα,
insulin, and dexamethasone and may result in remodeling of the extracellular matrix, changes in
stability of chromatin, or altered levels of cytokine production.
The induction of STATs 1 and 5 during adipogenesis strongly suggested that these
STATs would contribute to adipocyte biology. The identification of adipocyte genes as targets
of regulation by STATs clearly implicates STATs 1 and 5A as important modulators of
adipocyte biology. Although STATs 3 and 6 are also expressed in adipocytes, the expression of
these transcription factors is not regulated during adipogenesis. Activation of STAT6 in mature
adipocytes has not been reported, and we have not identified STAT3-regulated genes. Hence, it
is possible that STATs 3 and 6 may have functions in preadipocytes or serve to maintain general
cell functions, instead of modulating specific adipocyte genes. Identification of other gene
targets of STATs in adipocytes may reveal other roles for STATs. The epidemic of obesity
underscores the importance of continued research in all areas of adipocyte biology, including
effects of cytokines and the role of STATs in adipocytes.
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